Chemotherapy Resistance in Cancer: Mechanism and Roadmap to Evade Exploring Apoptosis
Abstract
Chemotherapy resistance indicates the non-responsiveness of cancer cells to the cytotoxic and inhibitory effects of chemo drugs attributed to either intrinsic or extrinsic resistance mechanisms in cancer cells. Studies so far indicate that drug resistance can be triggered by a multitude of factors such as the over-expression of drug efflux pumps, DNA repair mechanisms, modifications in the drug target such as point mutations and gene amplification, over-expression of anti-apoptotic proteins and down-regulation of pro-apoptotic signals, presence of cancer stem cells and immune-suppressive cells, excessive cytokine production, tumor heterogeneity, epigenetic changes, activation of alternate pro-survival signaling pathways, etc. Both host and tumor-related factors can contribute to therapy resistance. Currently, chemo resistance poses the foremost setback in the successful treatment of cancer, and it exerts significant stress on the available medical resources. Besides the costs associated with the treatment, patients go through severe emotional and physical trauma. Chemotherapy resistance is also a major contributor to accelerated metastasis and invasion. Dose-escalation is not always practical since the associated side effects may increase apart from increasing the treatment costs. Several studies are ongoing to address this issue productively, such as therapeutic molecules designed to restore the apoptotic machinery. Site-specific delivery of pro-apoptotic agents such as small molecules, antibodies, peptides, etc. targeting the apoptosis pathway is also thoroughly studied. Moreover, the efficacy of combination strategies is also a topic of research.
Keywords:
Apoptosis, Cancer, Chemotherapy, Drug resistance, Mechanisms
Downloads
Download data is not yet available.
References
Ahmed Juvale, I. I., Abdul Hamid, A. A., Abd Halim, K. B., & Che Has, A. T. (2022). P-glycoprotein: New insights into structure, physiological function, regulation and alterations in disease. Heliyon, 8(6), e09777. https://doi.org/10.1016/j.heliyon.2022.e09777
Alfarouk, K. O., Stock, C.-M., Taylor, S., Walsh, M., Muddathir, A. K., Verduzco, D., Bashir, A. H. H., Mohammed, O. Y., Elhassan, G. O., Harguindey, S., Reshkin, S. J., Ibrahim, M. E., & Rauch, C. (2015). Resistance to cancer chemotherapy: Failure in drug response from ADME to P-gp. Cancer Cell International, 15, 71. https://doi.org/10.1186/s12935-015-0221-1
Alwahsh, M., Farhat, J., Talhouni, S., Hamadneh, L., &Hergenröder, R. (2023). Bortezomib advanced mechanisms of action in multiple myeloma, solid and liquid tumors along with its novel therapeutic applications. EXCLI Journal, 22, 146–168. https://doi.org/10.17179/excli2022-5653
Alzahrani, A. M., & Rajendran, P. (2020). The Multifarious Link between Cytochrome P450s and Cancer. Oxidative Medicine and Cellular Longevity, 2020, 3028387. https://doi.org/10.1155/2020/3028387
Angelopoulou, E., Paudel, Y. N., &Piperi, C. (2020). Critical role of HOX transcript antisense intergenic RNA (HOTAIR) in gliomas. Journal of Molecular Medicine (Berlin, Germany), 98(11), 1525–1546. https://doi.org/10.1007/s00109-020-01984-x
Artykov, A. A., Yagolovich, A. V., Dolgikh, D. A., Kirpichnikov, M. P., Trushina, D. B., & Gasparian, M. E. (2021). Death Receptors DR4 and DR5 Undergo Spontaneous and Ligand-Mediated Endocytosis and Recycling Regardless of the Sensitivity of Cancer Cells to TRAIL. Frontiers in Cell and Developmental Biology, 9. https://www.frontiersin.org/articles/10.3389/fcell.2021.733688
Ashino, T., Nakamura, Y., Ohtaki, H., Iwakura, Y., &Numazawa, S. (2023). Interleukin-6 regulates the expression of hepatic canalicular efflux drug transporters after cecal ligation and puncture-induced sepsis: A comparison with lipopolysaccharide treatment. Toxicology Letters, 374, 40–47. https://doi.org/10.1016/j.toxlet.2022.12.003
Audia, J. E., & Campbell, R. M. (2016). Histone Modifications and Cancer. Cold Spring Harbor Perspectives in Biology, 8(4), a019521. https://doi.org/10.1101/cshperspect.a019521
Bahar, E., Han, S.-Y., Kim, J.-Y., & Yoon, H. (2022). Chemotherapy Resistance: Role of Mitochondrial and Autophagic Components. Cancers, 14(6), 1462. https://doi.org/10.3390/cancers14061462
Bahar, M. E., Kim, H. J., & Kim, D. R. (2023). Targeting the RAS/RAF/MAPK pathway for cancer therapy: From mechanism to clinical studies. Signal Transduction and Targeted Therapy, 8(1), 455. https://doi.org/10.1038/s41392-023-01705-z
Barboza, L. G. A., Dick Vethaak, A., Lavorante, B. R. B. O., Lundebye, A.-K., & Guilhermino, L. (2018). Marine microplastic debris: An emerging issue for food security, food safety and human health. Marine Pollution Bulletin, 133, 336–348. https://doi.org/10.1016/j.marpolbul.2018.05.047
Baxter, A. A., Lay, F. T., Poon, I. K. H., Kvansakul, M., & Hulett, M. D. (2017). Tumor cell membrane-targeting cationic antimicrobial peptides: Novel insights into mechanisms of action and therapeutic prospects. Cellular and Molecular Life Sciences: CMLS, 74(20), 3809–3825. https://doi.org/10.1007/s00018-017-2604-z
Berdis, A. J. (2017). Inhibiting DNA Polymerases as a Therapeutic Intervention against Cancer. Frontiers in Molecular Biosciences, 4. https://www.frontiersin.org/articles/10.3389/fmolb.2017.00078
Bertholee, D., Maring, J. G., & van Kuilenburg, A. B. P. (2017). Genotypes Affecting the Pharmacokinetics of Anticancer Drugs. Clinical Pharmacokinetics, 56(4), 317–337. https://doi.org/10.1007/s40262-016-0450-z
Bin, L., Thorburn, J., Thomas, L. R., Clark, P. E., Humphreys, R., & Thorburn, A. (2007). Tumor-derived Mutations in the TRAIL Receptor DR5 Inhibit TRAIL Signaling through the DR4 Receptor by Competing for Ligand Binding*. Journal of Biological Chemistry, 282(38), 28189–28194. https://doi.org/10.1074/jbc.M704210200
Bogdanov, A., Bogdanov, A., Chubenko, V., Volkov, N., Moiseenko, F., &Moiseyenko, V. (2022). Tumor acidity: From hallmark of cancer to target of treatment. Frontiers in Oncology, 12, 979154. https://doi.org/10.3389/fonc.2022.979154
Bou Antoun, N., &Chioni, A.-M.(2023). DysregulatedSignalling Pathways Driving Anticancer Drug Resistance. International Journal of Molecular Sciences, 24(15), 12222. https://doi.org/10.3390/ijms241512222
Brown, K. E. (2018). Revisiting CD28 Superagonist TGN1412 as Potential Therapeutic for Pediatric B Cell Leukemia: A Review. Diseases, 6(2), 41. https://doi.org/10.3390/diseases6020041
Bukowski, K., Kciuk, M., &Kontek, R. (2020).Mechanisms of Multidrug Resistance in Cancer Chemotherapy.International Journal of Molecular Sciences, 21(9), 3233.https://doi.org/10.3390/ijms21093233
Buscaglia LE, Li Y. (2011) Apoptosis and the target genes of microRNA-21. Chin J Cancer. 30(6):371-80. https://doi.org/10.5732/cjc.011.10132 .
Cadamuro, M., Brivio, S., Spirli, C., Joplin, R. E., Strazzabosco, M., & Fabris, L. (2017).Autocrine and Paracrine Mechanisms Promoting Chemoresistance in Cholangiocarcinoma. International Journal of Molecular Sciences, 18(1),149. https://doi.org/10.3390/ijms18010149
Campbell, K. J., & Leung, H. Y. (2021). Evasion of cell death: A contributory factor in prostate cancer development and treatment resistance. Cancer Letters, 520, 213–221. https://doi.org/10.1016/j.canlet.2021.07.045
Campbell, K. J., & Tait, S. W. G. (2018). Targeting BCL-2 regulated apoptosis in cancer. Open Biology, 8(5), 180002. https://doi.org/10.1098/rsob.180002
Castro-Muñoz, L. J., Vázquez Ulloa, E., Sahlgren, C., Lizano, M., De La Cruz-Hernández, E., & Contreras-Paredes, A. (2023). Modulating epigenetic modifications for cancer therapy (Review). Oncology Reports, 49(3), 59. https://doi.org/10.3892/or.2023.8496
Centurione, L., & Aiello, F. B. (2016). DNA Repair and Cytokines: TGF-β, IL-6, and Thrombopoietin as Different Biomarkers of Radioresistance. Frontiers in Oncology, 6, 175. https://doi.org/10.3389/fonc.2016.00175
Chakraborty, A. R., Robey, R. W., Luchenko, V. L., Zhan, Z., Piekarz, R. L., Gillet, J.-P., Kossenkov, A. V., Wilkerson, J., Showe, L. C., Gottesman, M. M., Collie, N. L., & Bates, S. E. (2013). MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: Rationale to combine romidepsin with an MEK inhibitor. Blood, 121(20), 4115–4125. https://doi.org/10.1182/blood-2012-08-449140
Chan, L. M. S., Lowes, S., & Hirst, B. H. (2004). The ABCs of drug transport in intestine and liver: Efflux proteins limiting drug absorption and bioavailability. European Journal of Pharmaceutical Sciences, 21(1), 25–51. https://doi.org/10.1016/j.ejps.2003.07.003
Chandrasekhar, C., Kumar, P. S., & Sarma, P. V. G. K. (2019). Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients. Scientific Reports, 9(1), Article 1. https://doi.org/10.1038/s41598-019-38672-x
Characteristics of the cancer stem cell niche and therapeutic strategies | Stem Cell Research & Therapy | Full Text.(n.d.). Retrieved February 17, 2024, from https://stemcellres.biomedcentral.com/articles/10.1186/s13287-022-02904-1
Chen, J.-J., Shen, H.-C.J., Rivera Rosado, L. A., Zhang, Y., Di, X., & Zhang, B. (2012). Mislocalization of death receptors correlates with cellular resistance to their cognate ligands in human breast cancer cells. Oncotarget, 3(8), 833–842. https://doi.org/10.18632/oncotarget.542
Chen, L., Zeng, Y., Zhou, S.-F., Chen, L., Zeng, Y., & Zhou, S.-F.(2018). Role of Apoptosis in Cancer Resistance to Chemotherapy. In Current Understanding of Apoptosis—Programmed Cell Death. In tech. https://doi.org/10.5772/intechopen.80056
Chibaya, L., Karim, B., Zhang, H., & Jones, S. N. (2021). Mdm2 phosphorylation by Akt regulates the p53 response to oxidative stress to promote cell proliferation and tumorigenesis. Proceedings of the National Academy of Sciences, 118(4), e2003193118. https://doi.org/10.1073/pnas.2003193118
Chota, A., George, B. P., & Abrahamse, H. (2021). Interactions of multidomain pro-apoptotic and anti-apoptotic proteins in cancer cell death. Oncotarget, 12(16), 1615–1626. https://doi.org/10.18632/oncotarget.28031
Chu, S., &Stochaj, U. (2020).Exploring near-infrared absorbing nanocarriers to overcome cancer drug resistance. Cancer Drug Resistance, 3(3), 302–333. https://doi.org/10.20517/cdr.2020.20
Comandatore, A., Immordino, B., Balsano, R., Capula, M., Garajovà, I., Ciccolini, J., Giovannetti, E., & Morelli, L. (2022).Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer. Diagnostics, 12(2), 286. https://doi.org/10.3390/diagnostics12020286
Cournoyer, S., Addioui, A., Belounis, A., Beaunoyer, M., Nyalendo, C., Le Gall, R., Teira, P., Haddad, E., Vassal, G., &Sartelet, H. (2019). GX15–070 (Obatoclax), a Bcl-2 family proteins inhibitor engenders apoptosis and pro-survival autophagy and increases Chemosensitivity in neuroblastoma. BMC Cancer, 19(1), 1018. https://doi.org/10.1186/s12885-019-6195-y
D’Aguanno, S., & Del Bufalo, D. (2020). Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer. Cells, 9(5), 1287. https://doi.org/10.3390/cells9051287
D’Alterio, C., Scala, S., Sozzi, G., Roz, L., & Bertolini, G. (2020).Paradoxical effects of chemotherapy on tumor relapse and metastasis promotion. Seminars in Cancer Biology, 60, 351–361. https://doi.org/10.1016/j.semcancer.2019.08.019
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997). Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery. Cell, 91(2), 231–241. https://doi.org/10.1016/S0092-8674(00)80405-5
de la Cruz-López, K. G., Castro-Muñoz, L. J., Reyes-Hernández, D. O., García-Carrancá, A., & Manzo-Merino, J. (2019). Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches. Frontiers in Oncology, 9, 1143. https://doi.org/10.3389/fonc.2019.01143
de la Torre, B. G., &Albericio, F. (2023). The Pharmaceutical Industry in 2022: An Analysis of FDA Drug Approvals from the Perspective of Molecules. Molecules, 28(3), 1038. https://doi.org/10.3390/molecules28031038
De Zio, D., Cianfanelli, V., & Cecconi, F. (2013). New Insights into the Link Between DNA Damage and Apoptosis. Antioxidants & Redox Signaling, 19(6), 559–571. https://doi.org/10.1089/ars.2012.4938
Delou, J. M. A., Souza, A. S. O., Souza, L. C. M., & Borges, H. L. (2019). Highlights in Resistance Mechanism Pathways for Combination Therapy. Cells, 8(9), 1013. https://doi.org/10.3390/cells8091013
Devanaboyina, M., Kaur, J., Whiteley, E., Lin, L., Einloth, K., Morand, S., Stanbery, L., Hamouda, D., & Nemunaitis, J. (2022). NF-κBSignaling in Tumor Pathways Focusing on Breast and Ovarian Cancer. Oncology Reviews, 16, 10568. https://doi.org/10.3389/or.2022.10568
Dine, J. L., O’Sullivan, C. C., Voeller, D., Greer, Y. E., Chavez, K. J., Conway, C. M., Sinclair, S., Stone, B., Amiri-Kordestani, L., Merchant, A. S., Hewitt, S. M., Steinberg, S. M., Swain, S. M., & Lipkowitz, S. (2016). The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. Breast Cancer Research and Treatment, 155(2), 235–251. https://doi.org/10.1007/s10549-015-3673-z
Dong, C., Wu, J., Chen, Y., Nie, J., & Chen, C. (2021). Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer. Frontiers in Pharmacology, 12, 628690. https://doi.org/10.3389/fphar.2021.628690
Du, Z., &Lovly, C. M. (2018).Mechanisms of receptor tyrosine kinase activation in cancer. Molecular Cancer, 17(1), 58. https://doi.org/10.1186/s12943-018-0782-4
Emran, T. B., Shahriar, A., Mahmud, A. R., Rahman, T., Abir, M. H., Siddiquee, Mohd. F.-R., Ahmed, H., Rahman, N., Nainu, F., Wahyudin, E., Mitra, S., Dhama, K., Habiballah, M. M., Haque, S., Islam, A., & Hassan, M. M. (2022). Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches. Frontiers in Oncology, 12. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.891652
Engle, K., & Kumar, G. (2022). Cancer multidrug-resistance reversal by ABCB1 inhibition: A recent update. European Journal of Medicinal Chemistry, 239, 114542. https://doi.org/10.1016/j.ejmech.2022.114542
Ferris, R. L., Harrington, K., Schoenfeld, J. D., Tahara, M., Esdar, C., Salmio, S., Schroeder, A., &Bourhis, J. (2023).Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck. Cancer Treatment Reviews, 113. https://doi.org/10.1016/j.ctrv.2022.102492
Gagnon, V., Van Themsche, C., Turner, S., Leblanc, V., & Asselin, E. (2008). Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol. Apoptosis: An International Journal on Programmed Cell Death, 13(2), 259–271. https://doi.org/10.1007/s10495-007-0165-6
Gao, P., Bauvy, C., Souquère, S., Tonelli, G., Liu, L., Zhu, Y., Qiao, Z., Bakula, D., Proikas-Cezanne, T., Pierron, G., Codogno, P., Chen, Q., &Mehrpour, M. (2010). The Bcl-2 Homology Domain 3 Mimetic Gossypol Induces Both Beclin 1-dependent and Beclin 1-independent Cytoprotective Autophagy in Cancer Cells. The Journal of Biological Chemistry, 285(33), 25570–25581. https://doi.org/10.1074/jbc.M110.118125
Giacomini, C., Granéli, C., Hicks, R., & Dazzi, F. (2023). The critical role of apoptosis in mesenchymal stromal cell therapeutics and implications in homeostasis and normal tissue repair. Cellular & Molecular Immunology, 20(6), Article 6. https://doi.org/10.1038/s41423-023-01018-9
Gluck, W. L., Gounder, M. M., Frank, R., Eskens, F., Blay, J. Y., Cassier, P. A., Soria, J.-C., Chawla, S., de Weger, V., Wagner, A. J., Siegel, D., De Vos, F., Rasmussen, E., &Henary, H. A. (2020). Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma. Investigational New Drugs, 38(3), 831–843. https://doi.org/10.1007/s10637-019-00840-1
Godwin, I., Anto, N. P., Bava, S. V., Babu, M. S., & Jinesh, G. G. (2021).Targeting K-Ras and apoptosis-driven cellular transformation in cancer. Cell Death Discovery, 7, 80. https://doi.org/10.1038/s41420-021-00457-5
Gouju, J., &Legeay, S. (2023). Pharmacokinetics of obese adults: Not only an increase in weight. Biomedicine & Pharmacotherapy, 166, 115281. https://doi.org/10.1016/j.biopha.2023.115281
Groen, K., van de Donk, N., Stege, C., Zweegman, S., &Nijhof, I. (2019).Carfilzomib for relapsed and refractory multiple myeloma. Cancer Management and Research, 11, 2663–2675. https://doi.org/10.2147/CMAR.S150653
Guan, Y., Wang, Y., Li, B., Shen, K., Li, Q., Ni, Y., & Huang, L. (2021).Mitophagy in carcinogenesis, drug resistance and anticancer therapeutics. Cancer Cell International, 21, 350. https://doi.org/10.1186/s12935-021-02065-w
Guo, M., Peng, Y., Gao, A., Du, C., & Herman, J. G. (2019). Epigenetic heterogeneity in cancer. Biomarker Research, 7(1), 23. https://doi.org/10.1186/s40364-019-0174-y
Han, W., Shi, L., Ren, L., Zhou, L., Li, T., Qiao, Y., & Wang, H. (2018). A nanomedicine approach enables co-delivery of cyclosporin A and gefitinib to potentiate the therapeutic efficacy in drug-resistant lung cancer. Signal Transduction and Targeted Therapy, 3(1), Article 1. https://doi.org/10.1038/s41392-018-0019-4
Hanahan, D. (2022). Hallmarks of Cancer: New Dimensions. Cancer Discovery, 12(1), 31–46. https://doi.org/10.1158/2159-8290.CD-21-1059
Hassanin, I., & Elzoghby, A. (2020). Albumin-based nanoparticles: A promising strategy to overcome cancer drug resistance. Cancer Drug Resistance, 3(4), 930–946. https://doi.org/10.20517/cdr.2020.68
Hasty, P., & Montagna, C. (2014). Chromosomal rearrangements in cancer. Molecular & Cellular Oncology, 1(1), e29904. https://doi.org/10.4161/mco.29904
He, X., Yan, Q., Kuang, G., Wang, Y., Cao, P., & Ou, C. (2018). Metastasis-associated lung adenocarcinoma transcript 1 regulates tumor progression: Old wine in a new bottle. Journal of Thoracic Disease, 10(Suppl 9), S1088–S1091. https://doi.org/10.21037/jtd.2018.04.13
Henke, E., Nandigama, R., & Ergün, S. (2020). Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy. Frontiers in Molecular Biosciences, 6, 160. https://doi.org/10.3389/fmolb.2019.00160
Hoeben, A., Joosten, E. A. J., & van den Beuken-van Everdingen, M. H. J. (2021).Personalized Medicine: Recent Progress in Cancer Therapy. Cancers, 13(2), 242. https://doi.org/10.3390/cancers13020242
Hu, J., Jing, H., & Lin, H. (2014). Sirtuin inhibitors as anticancer agents. Future Medicinal Chemistry, 6(8), 945–966. https://doi.org/10.4155/fmc.14.44
Hu, X., & Chen, W. (2021).Role of epithelial-mesenchymal transition in chemoresistance in pancreatic ductal adenocarcinoma. World Journal of Clinical Cases, 9(19), 4998–5006. https://doi.org/10.12998/wjcc.v9.i19.4998
Hu, Y., Yagüe, E., Zhao, J., Wang, L., Bai, J., Yang, Q., Pan, T., Zhao, H., Liu, J., & Zhang, J. (2018).Sabutoclax, pan-active BCL-2 protein family antagonist, overcomes drug resistance and eliminates cancer stem cells in breast cancer. Cancer Letters, 423, 47–59. https://doi.org/10.1016/j.canlet.2018.02.036
Huang, Y., Sun, G., Sun, X., Li, F., Zhao, L., Zhong, R., & Peng, Y. (2020). The Potential of Lonidamine in Combination with Chemotherapy and Physical Therapy in Cancer Treatment. Cancers, 12(11), 3332. https://doi.org/10.3390/cancers12113332
Icard, P., Shulman, S., Farhat, D., Steyaert, J.-M., Alifano, M., &Lincet, H. (2018). How the Warburg effect supports aggressiveness and drug resistance of cancer cells? Drug Resistance Updates, 38, 1–11. https://doi.org/10.1016/j.drup.2018.03.001
Janzer, A., German, N. J., Gonzalez-Herrera, K. N., Asara, J. M., Haigis, M. C., &Struhl, K. (2014). Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells. Proceedings of the National Academy of Sciences, 111(29), 10574–10579. https://doi.org/10.1073/pnas.1409844111
Je, H., Nam, G.-H., Kim, G. B., Kim, W., Kim, S. R., Kim, I.-S., & Lee, E. J. (2021).Overcoming therapeutic efficiency limitations against TRAIL-resistant tumors using re-sensitizing agent-loaded trimeric TRAIL-presenting nanocages. Journal of Controlled Release, 331, 7–18. https://doi.org/10.1016/j.jconrel.2021.01.016
Jeena, M. T., Kim, S., Jin, S., & Ryu, J.-H. (2019). Recent Progress in Mitochondria-Targeted Drug and Drug-Free Agents for Cancer Therapy. Cancers, 12(1), 4. https://doi.org/10.3390/cancers12010004
Jeong, S.-J., Dasgupta, A., Jung, K.-J., Um, J.-H., Burke, A., Park, H. U., & Brady, J. N. (2008). PI3K/AKT inhibition induces caspase-dependent apoptosis in HTLV-1 transformed cells. Virology, 370(2), 264–272. https://doi.org/10.1016/j.virol.2007.09.003
Jia, L.-T., Chen, S.-Y., & Yang, A.-G.(2012). Cancer gene therapy targeting cellular apoptosis machinery. Cancer Treatment Reviews, 38(7), 868–876. https://doi.org/10.1016/j.ctrv.2012.06.008
Jiang, G., Deng, W., Liu, Y., & Wang, C. (2020). General mechanism of JQ1 in inhibiting various types of cancer. Molecular Medicine Reports, 21(3), 1021–1034. https://doi.org/10.3892/mmr.2020.10927
Jim Yen, M., Shih, I.-M., Velculescu, V. E., & Wang, T.-L. (2006). Amplification in DNA Copy Numbers as a Mechanism of Acquired Drug Resistance. In B. A. Teicher (Ed.), Cancer Drug Resistance (pp. 531–540). Humana Press. https://doi.org/10.1007/978-1-59745-035-5_28
Jones, V. S., Huang, R.-Y., Chen, L.-P., Chen, Z.-S., Fu, L., & Huang, R.-P. (2016). Cytokines in cancer drug resistance: Cues to new therapeutic strategies. BiochimicaetBiophysicaActa (BBA) - Reviews on Cancer, 1865(2), 255–265. https://doi.org/10.1016/j.bbcan.2016.03.005
Joshi, R. S., Kanugula, S. S., Sudhir, S., Pereira, M. P., Jain, S., & Aghi, M. K. (2021). The Role of Cancer-Associated Fibroblasts in Tumor Progression. Cancers, 13(6), 1399. https://doi.org/10.3390/cancers13061399
Jurkovicova, D., Neophytou, C. M., Gašparović, A. Č., & Gonçalves, A. C. (2022). DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities. International Journal of Molecular Sciences, 23(23), 14672. https://doi.org/10.3390/ijms232314672
Karthika, C., Sureshkumar, R., Zehravi, M., Akter, R., Ali, F., Ramproshad, S., Mondal, B., Tagde, P., Ahmed, Z., Khan, F. S., Rahman, M. H., &Cavalu, S. (2022). Multidrug Resistance of Cancer Cells and the Vital Role of P-Glycoprotein. Life, 12(6), Article 6. https://doi.org/10.3390/life12060897
Kartikasari, A. E. R., Huertas, C. S., Mitchell, A., & Plebanski, M. (2021).Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis. Frontiers in Oncology, 11. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.692142
Kashiwagi, H., McDunn, J. E., Goedegebuure, P. S., Gaffney, M. C., Chang, K., Trinkaus, K., Piwnica-Worms, D., Hotchkiss, R. S., & Hawkins, W. G. (2007). TAT-Bim induces extensive apoptosis in cancer cells. Annals of Surgical Oncology, 14(5), 1763–1771. https://doi.org/10.1245/s10434-006-9298-z
Ko, Y. T., Falcao, C., &Torchilin, V. P. (2009). Cationic liposomes loaded with pro-apoptotic peptide D-(KLAKLAK)2 and bcl-2 antisense oligodeoxynucleotide G3139 for enhanced anti-cancer therapy. Molecular Pharmaceutics, 6(3), 971–977. https://doi.org/10.1021/mp900006h
Konopleva, M. Y., Röllig, C., Cavenagh, J., Deeren, D., Girshova, L., Krauter, J., Martinelli, G., Montesinos, P., Schäfer, J. A., Ottmann, O., Petrini, M., Pigneux, A., Rambaldi, A., Recher, C., Rodriguez-Veiga, R., Taussig, D., Vey, N., Yoon, S.-S., Ott, M., … Wei, A. H. (2022). Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: Results of the MIRROS trial. Blood Advances, 6(14), 4147–4156. https://doi.org/10.1182/bloodadvances.2021006303
Kozlova, N., Grossman, J. E., Iwanicki, M. P., & Muranen, T. (2020).The interplay of the extracellular matrix and stromal cells as a drug target in stroma-rich cancers. Trends in Pharmacological Sciences, 41(3), 183–198. https://doi.org/10.1016/j.tips.2020.01.001
Krendyukov, A., &Gieffers, C. (2019). Asunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignancies. Cancer Management and Research, 11, 8095. https://doi.org/10.2147/CMAR.S216675
Kumar, S., Kushwaha, P. P., & Gupta, S. (2019). Emerging targets in cancer drug resistance. Cancer Drug Resistance, 2(2), 161–177. https://doi.org/10.20517/cdr.2018.27
Lakshminarasimhan, R., & Liang, G. (2016).The Role of DNA Methylation in Cancer. Advances in Experimental Medicine and Biology, 945, 151–172. https://doi.org/10.1007/978-3-319-43624-1_7
Lathia, J. D., Mack, S. C., Mulkearns-Hubert, E. E., Valentim, C. L. L., & Rich, J. N. (2015). Cancer stem cells in glioblastoma. Genes & Development, 29(12), 1203–1217. https://doi.org/10.1101/gad.261982.115
Lee, S. H., Shin, M. S., Kim, H. S., Lee, H. K., Park, W. S., Kim, S. Y., Lee, J. H., Han, S. Y., Park, J. Y., Oh, R. R., Jang, J. J., Han, J. Y., Lee, J. Y., & Yoo, N. J. (1999). Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer research, 59(22), 5683–5686.
Lee, S., Rauch, J., &Kolch, W. (2020).Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity.International Journal of Molecular Sciences, 21(3), 1102. https://doi.org/10.3390/ijms21031102
Leeuwen, R. W. F. van, Jansman, F. G. A., Bemt, P. M. L. A. van den, Man, F. de, Piran, F., Vincenten, I., Jager, A., Rijneveld, A. W., Brugma, J. D., Mathijssen, R. H. J., & Gelder, T. van. (2015). Drug–drug interactions in patients treated for cancer: A prospective study on clinical interventions. Annals of Oncology, 26(5), 992–997. https://doi.org/10.1093/annonc/mdv029
Lei, W., Duan, R., Li, J., Liu, X., Huston, A., Boyce, B. F., & Yao, Z. (2020). The IAP Antagonist SM-164 Eliminates Triple-Negative Breast Cancer Metastasis to Bone and Lung in Mice. Scientific Reports, 10(1), 7004. https://doi.org/10.1038/s41598-020-64018-z
Li, H.-J., Gong, X., Li, Z.-K., Qin, W., He, C.-X., Xing, L., Zhou, X., Zhao, D., & Cao, H.-L. (2021). Role of Long Non-coding RNAs on Bladder Cancer. Frontiers in Cell and Developmental Biology, 9, 672679. https://doi.org/10.3389/fcell.2021.672679
Li, X., Qiu, Z., Jin, Q., Chen, G., & Guo, M. (2018). Cell Cycle Arrest and Apoptosis in HT-29 Cells Induced by Dichloromethane Fraction From Toddalia asiatica (L.) Lam. Frontiers in Pharmacology, 9. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.00629
Lim, B., Greer, Y., Lipkowitz, S., & Takebe, N. (2019). Novel Apoptosis-Inducing Agents for the Treatment of Cancer, a New Arsenal in the Toolbox. Cancers, 11(8), 1087. https://doi.org/10.3390/cancers11081087
Lin, J. H., & Yamazaki, M. (2003). Role of P-glycoprotein in pharmacokinetics: Clinical implications. Clinical Pharmacokinetics, 42(1), 59–98. https://doi.org/10.2165/00003088-200342010-00003
Lin, J., Song, T., Li, C., & Mao, W. (2020). GSK-3β in DNA repair, apoptosis, and resistance of chemotherapy, radiotherapy of cancer. Biochimicaet Biophysica Acta (BBA) - Molecular Cell Research, 1867(5), 118659. https://doi.org/10.1016/j.bbamcr.2020.118659
Lin, X., Xiao, Z., Chen, T., Liang, S. H., & Guo, H. (2020).Glucose Metabolism on Tumor Plasticity, Diagnosis, and Treatment. Frontiers in Oncology, 10, 317. https://doi.org/10.3389/fonc.2020.00317
Liu, G., Chen, T., Zhang, X., Ma, X., & Shi, H. (2022).Small molecule inhibitors targeting the cancers. Med Comm, 3(4), e181. https://doi.org/10.1002/mco2.181
Liu, K., Gao, L., Ma, X., Huang, J.-J., Chen, J., Zeng, L., Ashby, C. R., Zou, C., & Chen, Z.-S. (2020). Long non-coding RNAs regulate drug resistance in cancer. Molecular Cancer, 19, 54. https://doi.org/10.1186/s12943-020-01162-0
Liu, R., Chen, Y., Liu, G., Li, C., Song, Y., Cao, Z., Li, W., Hu, J., Lu, C., & Liu, Y. (2020). PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death & Disease, 11(9), Article 9. https://doi.org/10.1038/s41419-020-02998-6
Liu, Y., Zhang, H., Cui, H., Zhang, F., Zhao, L., Liu, Y., & Meng, Q. (2022). Combined and targeted drugs delivery system for colorectal cancer treatment: Conatumumab decorated, reactive oxygen species sensitive irinotecan prodrug and quercetin co-loaded nanostructured lipid carriers. Drug Delivery, 29(1), 342–350. https://doi.org/10.1080/10717544.2022.2027573
Lønning, P. E., & Knappskog, S. (2013). Mapping genetic alterations causing chemoresistance in cancer: Identifying the roads by tracking the drivers. Oncogene, 32(46), Article 46. https://doi.org/10.1038/onc.2013.48
Luo, Z.-D., Wang, Y.-F., Zhao, Y.-X., Yu, L.-C., Li, T., Fan, Y.-J., Zeng, S.-J., Zhang, Y.-L., Zhang, Y., & Zhang, X. (2023).Emerging roles of non-coding RNAs in colorectal cancer oxaliplatin resistance and liquid biopsy potential. World Journal of Gastroenterology, 29(1), 1–18. https://doi.org/10.3748/wjg.v29.i1.1
Magee, P., Shi, L., & Garofalo, M. (2015).Role of microRNAs in chemoresistance. Annals of Translational Medicine, 3(21), 332. https://doi.org/10.3978/j.issn.2305-5839.2015.11.32
Mahgoub, E. O., Cho, W. C., Sharifi, M., Falahati, M., Zeinabad, H. A., Mare, H. E., & Hasan, A. (2024).Role of functional genomics in identifying cancer drug resistance and overcoming cancer relapse. Heliyon, 10(1), e22095. https://doi.org/10.1016/j.heliyon.2023.e22095
Malla, W. A., Arora, R., Khan, R. I. N., Mahajan, S., & Tiwari, A. K. (2020). Apoptin as a Tumor-Specific Therapeutic Agent: Current Perspective on Mechanism of Action and Delivery Systems. Frontiers in Cell and Developmental Biology, 8, 524. https://doi.org/10.3389/fcell.2020.00524
Marusyk, A., Janiszewska, M., & Polyak, K. (2020). Intratumor heterogeneity: The Rosetta stone of therapy resistance. Cancer Cell, 37(4), 471–484. https://doi.org/10.1016/j.ccell.2020.03.007
Matsui, A., Ihara, T., Suda, H., Mikami, H., & Semba, K. (2013). Gene amplification: Mechanisms and involvement in cancer. BioMolecular Concepts, 4(6), 567–582. https://doi.org/10.1515/bmc-2013-0026
Matuszewska, K., Pereira, M., Petrik, D., Lawler, J., & Petrik, J. (2021). Normalizing Tumor Vasculature to Reduce Hypoxia, Enhance Perfusion, and Optimize Therapy Uptake. Cancers, 13(17), 4444. https://doi.org/10.3390/cancers13174444
Mechanisms of acquired tumor drug resistance. (2019). Biochimicaet Biophysica Acta (BBA) - Reviews on Cancer, 1872(2), 188310. https://doi.org/10.1016/j.bbcan.2019.188310
Meng, C.-Y., Zhao, Z.-Q., Bai, R., Zhao, W., Wang, Y.-X., Sun, L., Sun, C., Feng, W., & Guo, S.-B. (2020). MicroRNA-22 regulates autophagy and apoptosis in cisplatin resistance of osteosarcoma. Molecular Medicine Reports, 22(5), 3911–3921. https://doi.org/10.3892/mmr.2020.11447
MengieAyele, T., Tilahun Muche, Z., BehaileTeklemariam, A., Bogale Kassie, A., &ChekolAbebe, E. (2022). Role of JAK2/STAT3 Signaling Pathway in the Tumorigenesis, Chemotherapy Resistance, and Treatment of Solid Tumors: A Systemic Review. Journal of Inflammation Research, 15, 1349–1364. https://doi.org/10.2147/JIR.S353489
Mohammad, R. M., Muqbil, I., Lowe, L., Yedjou, C., Hsu, H.-Y., Lin, L.-T., Siegelin, M. D., Fimognari, C., Kumar, N. B., Dou, Q. P., Yang, H., Samadi, A. K., Russo, G. L., Spagnuolo, C., Ray, S. K., Chakrabarti, M., Morre, J. D., Coley, H. M., Honoki, K., … Azmi, A. S. (2015). Broad targeting of resistance to apoptosis in cancer. Seminars in Cancer Biology, 35, S78–S103. https://doi.org/10.1016/j.semcancer.2015.03.001
Muz, B., Ghazarian, R. N., Ou, M., Luderer, M. J., Kusdono, H. D., & Azab, A. K. (2016).Spotlight on ixazomib: Potential in the treatment of multiple myeloma. Drug Design, Development and Therapy, 10, 217–226. https://doi.org/10.2147/DDDT.S93602
Nanayakkara, A. K., Follit, C. A., Chen, G., Williams, N. S., Vogel, P. D., & Wise, J. G. (2018). Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells. Scientific Reports, 8(1), 967. https://doi.org/10.1038/s41598-018-19325-x
Neophytou, C. M., Trougakos, I. P., Erin, N., &Papageorgis, P. (2021).Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance. Cancers, 13(17), Article 17. https://doi.org/10.3390/cancers13174363
Nishikawa, S., & Iwakuma, T. (2023). Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials. Cancers, 15(2), 429. https://doi.org/10.3390/cancers15020429
Nor Hisam, N. S., Ugusman, A., Rajab, N. F., Ahmad, M. F., Fenech, M., Liew, S. L., & Mohamad Anuar, N. N. (2021). Combination Therapy of Navitoclax with Chemotherapeutic Agents in Solid Tumors and Blood Cancer: A Review of Current Evidence. Pharmaceutics, 13(9), 1353. https://doi.org/10.3390/pharmaceutics13091353
Novikov, N. M., Zolotaryova, S. Y., Gautreau, A. M., & Denisov, E. V. (2021). Mutational drivers of cancer cell migration and invasion. British Journal of Cancer, 124(1), Article 1. https://doi.org/10.1038/s41416-020-01149-0
Nussinov, R., Tsai, C.-J., & Jang, H. (2017).A New View of Pathway-Driven Drug Resistance in Tumor Proliferation. Trends in Pharmacological Sciences, 38(5), 427–437. https://doi.org/10.1016/j.tips.2017.02.001
Ozcan, G. (2023). The hypoxia-inducible factor-1α in stemness and resistance to chemotherapy in gastric cancer: Future directions for therapeutic targeting. Frontiers in Cell and Developmental Biology, 11, 1082057. https://doi.org/10.3389/fcell.2023.1082057
Palamaris, K., Felekouras, E., & Sakellariou, S. (2021). Epithelial to Mesenchymal Transition: Key Regulator of Pancreatic Ductal Adenocarcinoma Progression and Chemoresistance. Cancers, 13(21), 5532. https://doi.org/10.3390/cancers13215532
Papadopoulou, A., Govina, O., Tsatsou, I., Mantzorou, M., Mantoudi, A., Tsiou, C., &Adamakidou, T. (2022).Quality of life, distress, anxiety and depression of ambulatory cancer patients receiving chemotherapy. Medicine and Pharmacy Reports, 95(4), 418–429. https://doi.org/10.15386/mpr-2458
Patel, A. B., O’Hare, T., & Deininger, M. W. (2017).Mechanisms of resistance to ABL kinase inhibition in CML and the development of next generation ABL kinase inhibitors. Hematology/Oncology Clinics of North America, 31(4), 589–612. https://doi.org/10.1016/j.hoc.2017.04.007
Pathak, S., Singh, V., Kumar, N., &Jayandharan, G. R. (2023). Inducible caspase 9-mediated suicide gene therapy using AAV6 vectors in a murine model of breast cancer. Molecular Therapy Methods & Clinical Development, 31. https://doi.org/10.1016/j.omtm.2023.101166
Pavlíková, L., Šereš, M., Breier, A., &Sulová, Z. (2022).The Roles of microRNAs in Cancer Multidrug Resistance. Cancers, 14(4), 1090. https://doi.org/10.3390/cancers14041090
Pekarsky, Y., Balatti, V., & Croce, C. M. (2018). BCL2 and miR-15/16: From gene discovery to treatment. Cell Death & Differentiation, 25(1), Article 1. https://doi.org/10.1038/cdd.2017.159
Pfeffer, C. M., & Singh, A. T. K. (2018). Apoptosis: A Target for Anticancer Therapy. International Journal of Molecular Sciences, 19(2), 448. https://doi.org/10.3390/ijms19020448
Phi, L. T. H., Sari, I. N., Yang, Y.-G., Lee, S.-H., Jun, N., Kim, K. S., Lee, Y. K., & Kwon, H. Y. (2018). Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment. Stem Cells International, 2018, 5416923. https://doi.org/10.1155/2018/5416923
Pojani, E., & Barlocco, D. (2021).Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy. Current Medicinal Chemistry, 28(7), 1290–1303. https://doi.org/10.2174/0929867327666200203113926
Pote, M. S., & Gacche, R. N. (2023).ATP-binding cassette efflux transporters and MDR in cancer. Drug Discovery Today, 28(5), 103537. https://doi.org/10.1016/j.drudis.2023.103537
Qian, S., Wei, Z., Yang, W., Huang, J., Yang, Y., & Wang, J. (2022).The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. Frontiers in Oncology, 12, 985363. https://doi.org/10.3389/fonc.2022.985363
Rahman, H., Rudrow, A., Carneglia, J., Joly, S. S. P., Nicotera, D., Naldrett, M., Choy, J., Ambudkar, S. V., & Golin, J. (2020). Nonsynonymous Mutations in Linker-2 of the Pdr5 Multidrug Transporter Identify a New RNA Stability Element. G3 (Bethesda, Md.), 10(1), 357–369. https://doi.org/10.1534/g3.119.400863
Rajan, P. K., Udoh, U.-A., Sanabria, J. D., Banerjee, M., Smith, G., Schade, M. S., Sanabria, J., Sodhi, K., Pierre, S., Xie, Z., Shapiro, J. I., & Sanabria, J. (2020). The Role of Histone Acetylation-/Methylation-Mediated Apoptotic Gene Regulation in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 21(23), 8894. https://doi.org/10.3390/ijms21238894
Ramadhani, D., Maharani, R., Gazzali, A. M., & Muchtaridi, M. (2022). Cyclic Peptides for the Treatment of Cancers: A Review. Molecules, 27(14), 4428. https://doi.org/10.3390/molecules27144428
Rangel, L. P., Ferretti, G. D. S., Costa, C. L., Andrade, S. M. M. V., Carvalho, R. S., Costa, D. C. F., & Silva, J. L. (2019). P53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells. The Journal of Biological Chemistry, 294(10), 3670–3682. https://doi.org/10.1074/jbc.RA118.004671
Regulated cell death (RCD) in cancer: Key pathways and targeted therapies | Signal Transduction and Targeted Therapy. (n.d.). Retrieved February 18, 2024, from https://www.nature.com/articles/s41392-022-01110-y
Ren, L., & Yu, Y. (2018).The role of miRNAs in the diagnosis, chemoresistance, and prognosis of pancreatic ductal adenocarcinoma. Therapeutics and Clinical Risk Management, 14, 179–187. https://doi.org/10.2147/TCRM.S154226
Rieger, C., Huebner, D., Temme, A., Wirth, M. P., & Fuessel, S. (2015). Antisense- and siRNA-mediated inhibition of the anti-apoptotic gene Bcl-xL for chemosensitization of bladder cancer cells. International Journal of Oncology, 47(3), 1121–1130. https://doi.org/10.3892/ijo.2015.3096
Roberts, A. W., Wei, A. H., & Huang, D. C. S. (2021).BCL2 and MCL1 inhibitors for hematologic malignancies. Blood, 138(13), 1120–1136. https://doi.org/10.1182/blood.2020006785
Roberts, J. A., Pea, F., & Lipman, J. (2013).The Clinical Relevance of Plasma Protein Binding Changes. Clinical Pharmacokinetics, 52(1), 1–8. https://doi.org/10.1007/s40262-012-0018-5
Robey, R. W., Pluchino, K. M., Hall, M. D., Fojo, A. T., Bates, S. E., & Gottesman, M. M. (2018).Revisiting the role of efflux pumps in multidrug-resistant cancer. Nature Reviews Cancer, 18(7), 452–464. https://doi.org/10.1038/s41568-018-0005-8
Roth, C., Pantel, K., Müller, V., Rack, B., Kasimir-Bauer, S., Janni, W., & Schwarzenbach, H. (2011). Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression. BMC Cancer, 11(1), 4. https://doi.org/10.1186/1471-2407-11-4
Rudzińska, M., Daglioglu, C., Savvateeva, L. V., Kaci, F. N., Antoine, R., &ZamyatninJr, A. A. (2021). Current Status and Perspectives of Protease Inhibitors and Their Combination with Nanosized Drug Delivery Systems for Targeted Cancer Therapy. Drug Design Development and Therapy, 15, 9–20. https://doi.org/10.2147/DDDT.S285852
Sano, R., & Reed, J. C. (2013). ER stress-induced cell death mechanisms. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, 1833(12), 3460-3470.. https://doi.org/10.1016/j.bbamcr.2013.06.028
Segal, E. M., Flood, M. R., Mancini, R. S., Whiteman, R. T., Friedt, G. A., Kramer, A. R., & Hofstetter, M. A. (2014). Oral Chemotherapy Food and Drug Interactions: A Comprehensive Review of the Literature. Journal of Oncology Practice, 10(4), e255–e268. https://doi.org/10.1200/JOP.2013.001183
Shahar, N., & Larisch, S. (2020). Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance. Drug Resistance 52, 100712. https://doi.org/10.1016/j.drup.2020.100712
Shin, M. S., Kim, H. S., Lee, S. H., Park, W. S., Kim, S. Y., Park, J. Y., Lee, J. H., Lee, S. K., Lee, S. N., Jung, S. S., Han, J. Y., Kim, H., Lee, J. Y., & Yoo, N. J. (n.d.). Mutations of Tumor Necrosis Factor-related Apoptosis-inducing Ligand Receptor 1 (TRAIL-R1) and Receptor 2 (TRAIL-R2) Genes in Metastatic Breast Cancers.
Shoshan-Barmatz, V., Arif, T., &Shteinfer-Kuzmine, A. (2023). Apoptotic proteins with non-apoptotic activity: Expression and function in cancer. Apoptosis, 28(5), 730–753. https://doi.org/10.1007/s10495-023-01835-3
Sjöstedt, N., Holvikari, K., Tammela, P., & Kidron, H. (2017). Inhibition of Breast Cancer Resistance Protein and Multidrug Resistance Associated Protein 2 by Natural Compounds and Their Derivatives. Molecular Pharmaceutics, 14(1), 135–146. https://doi.org/10.1021/acs.molpharmaceut.6b00754
Snajdauf, M., Havlova, K., Vachtenheim, J., Ozaniak, A., Lischke, R., Bartunkova, J., Smrz, D., &Strizova, Z. (2021). The TRAIL in the Treatment of Human Cancer: An Update on Clinical Trials. Frontiers in Molecular Biosciences, 8, 628332. https://doi.org/10.3389/fmolb.2021.628332
Sodani, K., Patel, A., Kathawala, R. J., & Chen, Z.-S. (2012). Multidrug resistance associated proteins in multidrug resistance. Chinese Journal of Cancer, 31(2), 58–72. https://doi.org/10.5732/cjc.011.10329
Solon, A. L., Zaniewski, T. M., O’Brien, P., Clasby, M., Hancock, W. O., & Ohi, R. (2022). Synergy between inhibitors of two mitotic spindle assembly motors undermines an adaptive response. Molecular Biology of the Cell, 33(14), ar132. https://doi.org/10.1091/mbc.E22-06-0225
Sonar, S., & Lal, G. (2015).Role of Tumor Necrosis Factor Superfamily in Neuroinflammation and Autoimmunity.Frontiers in Immunology, 6. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2015.00364
Song, E. Z., Wang, X., Philipson, B. I., Zhang, Q., Thokala, R., Zhang, L., Assenmacher, C.-A., Binder, Z. A., Ming, G.-L., O’Rourke, D. M., Song, H., & Milone, M. C. (2022). The IAP antagonist birinapant enhances chimeric antigen receptor T cell therapy for glioblastoma by overcoming antigen heterogeneity. Molecular Therapy Oncolytics, 27, 288–304. https://doi.org/10.1016/j.omto.2022.11.004
Soria, J.-C., Smit, E., Khayat, D., Besse, B., Yang, X., Hsu, C.-P., Reese, D., Wiezorek, J., & Blackhall, F. (2010). Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. Journal of Clinical Oncology: 28(9), 1527–1533. https://doi.org/10.1200/JCO.2009.25.4847
Sriraman, S. K., Aryasomayajula, B., &Torchilin, V. P. (2014). Barriers to drug delivery in solid tumors. Tissue Barriers, 2, e29528. https://doi.org/10.4161/tisb.29528
Stefanski, C. D., Keffler, K., McClintock, S., Milac, L., & Prosperi, J. R. (2019). APC loss affects DNA damage repair causing doxorubicin resistance in breast cancer cells. Neoplasia, 21(12), 1143–1150. https://doi.org/10.1016/j.neo.2019.09.002
Statello L, Guo CJ, Chen LL, Huarte M. (2021) Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 22(2):96-118. https://doi.org/10.1038/s41580-020-00315-9.
Stylianopoulos, T., Munn, L. L., & Jain, R. K. (2018). Reengineering the Tumor Vasculature: Improving Drug Delivery and Efficacy. Trends in Cancer, 4(4), 258–259. https://doi.org/10.1016/j.trecan.2018.02.010
Sun, J., Wei, Q., Zhou, Y., Wang, J., Liu, Q., & Xu, H. (2017).A systematic analysis of FDA-approved anticancer drugs. BMC Systems Biology, 11(Suppl 5), 87. https://doi.org/10.1186/s12918-017-0464-7
Sun, Y., Li, J., Sun, Y., Zhao, R., Wang, L., Song, W., Wang, Z., Wang, J., Wei, L., Zhao, Y., Song, Y., & Hu, Z. (2019). A Stable Pep2-proapoptotic Peptide Inducing Apoptosis of Acute Myeloid Leukemia Cells by Down-Regulating EZH2. Cellular and Molecular Bioengineering, 13(2), 165–177. https://doi.org/10.1007/s12195-019-00605-z
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660
Tang, B., Tang, F., Wang, Z., Qi, G., Liang, X., Li, B., Yuan, S., Liu, J., Yu, S., & He, S. (2016). Upregulation of Akt/NF-κB-regulated inflammation and Akt/Bad-related apoptosis signaling pathway involved in hepatic carcinoma process: Suppression by carnosic acid nanoparticle. International Journal of Nanomedicine, 11, 6401–6420. https://doi.org/10.2147/IJN.S101285
Tao H, Cheng L, Yang R. (2020) Downregulation of miR-34a Promotes Proliferation and Inhibits Apoptosis of Rat Osteoarthritic Cartilage Cells by Activating PI3K/Akt Pathway. ClinInterv Aging. 16;15:373-385. https://doi.org/10.2147/CIA.S241855
Tashker, J. S., Olson, M., & Kornbluth, S. (2002). Post–Cytochrome c Protection from Apoptosis Conferred by a MAPK Pathway in Xenopus Egg Extracts. Molecular Biology of the Cell, 13(2), 393–401. https://doi.org/10.1091/mbc.01-06-0291
Teh, C. E., Peng, H., Luo, M.-X., Tan, T., Trussart, M., Howson, L. J., Chua, C. C., Muttiah, C., Brown, F., Ritchie, M. E., Wei, A. H., Roberts, A. W., Bryant, V. L., Anderson, M. A., Lindeman, G. J., Huang, D. C. S., Thijssen, R., & Gray, D. H. D. (2023). Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cells. Blood Advances, 7(12), 2733–2745. https://doi.org/10.1182/bloodadvances.2022008221
Terada, T., & Hira, D. (2015). Intestinal and hepatic drug transporters: Pharmacokinetic, pathophysiological, and pharmacogenetic roles. Journal of Gastroenterology, 50(5), 508–519. https://doi.org/10.1007/s00535-015-1061-4
Thapa, B., Kc, R., & Uludağ, H. (2020). TRAIL therapy and prospective developments for cancer treatment. Journal of Controlled Release, 326, 335–349. https://doi.org/10.1016/j.jconrel.2020.07.013
Tie, Y., Tang, F., Wei, Y.-Q., & Wei, X.-W. (2022). Immunosuppressive cells in cancer: Mechanisms and potential therapeutic targets. Journal of Hematology & Oncology, 15(1), 61. https://doi.org/10.1186/s13045-022-01282-8
Townsend, P. A., Kozhevnikova, M. V., Cexus, O. N. F., Zamyatnin, A. A., &Soond, S. M. (2021). BH3-mimetics: Recent developments in cancer therapy. Journal of Experimental & Clinical Cancer Research, 40(1), 355. https://doi.org/10.1186/s13046-021-02157-5
Traube, F. R., Brás, N. F., Roos, W. P., Sommermann, C. C., Diehl, T., Mayer, R. J., Ofial, A. R., Müller, M., Zipse, H., & Carell, T. (2022). Epigenetic Anti-Cancer Treatment With a Stabilized Carbocyclic Decitabine Analogue. Chemistry–A European Journal, 28(26), e202200640. https://doi.org/10.1002/chem.202200640
Tune, B. X. J., Sim, M. S., Poh, C. L., Guad, R. M., Woon, C. K., Hazarika, I., Das, A., Gopinath, S. C. B., Rajan, M., Sekar, M., Subramaniyan, V., Fuloria, N. K., Fuloria, S., Batumalaie, K., & Wu, Y. S. (2022). Matrix Metalloproteinases in Chemoresistance: Regulatory Roles, Molecular Interactions, and Potential Inhibitors. Journal of Oncology, 2022, 3249766. https://doi.org/10.1155/2022/3249766
Twomey, J. D., Kim, S.-R., Zhao, L., Bozza, W. P., & Zhang, B. (2015).Spatial dynamics of TRAIL death receptors in cancer cells. Drug Resistance Updates, 19, 13–21. https://doi.org/10.1016/j.drup.2015.02.001
Ulldemolins, A., Seras-Franzoso, J., Andrade, F., Rafael, D., Abasolo, I., Gener, P., & Schwartz Jr, S. (2021). Perspectives of nano-carrier drug delivery systems to overcome cancer drug resistance in the clinics. Cancer Drug Resistance, 4(1), 44–68. https://doi.org/10.20517/cdr.2020.59
von Pawel, J., Harvey, J. H., Spigel, D. R., Dediu, M., Reck, M., Cebotaru, C. L., Humphreys, R. C., Gribbin, M. J., Fox, N. L., & Camidge, D. R. (2014). Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Clinical Lung Cancer, 15(3), 188-196.e2. https://doi.org/10.1016/j.cllc.2013.12.005
Walker, Z. J., Xue, S., Jones, M. P., & Ravindran, A. V. (2021). Depression, Anxiety, and Other Mental Disorders in Patients With Cancer in Low- and Lower-Middle–Income Countries: A Systematic Review and Meta-Analysis. JCO Global Oncology, 7, GO.21.00056. https://doi.org/10.1200/GO.21.00056
Wang, H., Guo, M., Wei, H., & Chen, Y. (2021).Targeting MCL-1 in cancer: Current status and perspectives. Journal of Hematology & Oncology, 14(1), 67. https://doi.org/10.1186/s13045-021-01079-1
Wang, J., Tao, J., Jia, S., Wang, M., Jiang, H., & Du, Z. (2021). The Protein-Binding Behavior of Platinum Anticancer Drugs in Blood Revealed by Mass Spectrometry. Pharmaceuticals, 14(2), 104. https://doi.org/10.3390/ph14020104
Wang, M., Yu, F., Zhang, Y., Zhang, L., Chang, W., & Wang, K. (2022).The Emerging Roles of Circular RNAs in the Chemoresistance of Gastrointestinal Cancer. Frontiers in Cell and Developmental Biology, 10, 821609. https://doi.org/10.3389/fcell.2022.821609
Wang, X., Zhang, H., & Chen, X. (2019).Drug resistance and combating drug resistance in cancer. Cancer Drug Resistance, 2(2), 141–160. https://doi.org/10.20517/cdr.2019.10
Ward, G. A., Lewis, E. J., Ahn, J. S., Johnson, C. N., Lyons, J. F., Martins, V., Munck, J. M., Rich, S. J., Smyth, T., Thompson, N. T., Williams, P. A., Wilsher, N. E., Wallis, N. G., &Chessari, G. (2018). ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth. Molecular Cancer Therapeutics, 17(7), 1381–1391. https://doi.org/10.1158/1535-7163.MCT-17-0848
Wawruszak, A., Borkiewicz, L., Okon, E., Kukula-Koch, W., Afshan, S., &Halasa, M. (2021).Vorinostat (SAHA) and Breast Cancer: An Overview. Cancers, 13(18), 4700. https://doi.org/10.3390/cancers13184700
Wolf, A. M. (2021). The tumor suppression theory of aging. Mechanisms of Ageing and Development, 200, 111583. https://doi.org/10.1016/j.mad.2021.111583
World Cancer Day 2023: Close the care gap - PAHO/WHO | Pan American Health Organization. (n.d.). Retrieved February 17, 2024, from https://www.paho.org/en/campaigns/world-cancer-day-2023-close-care-gap
Wu, B., Zhang, Y., Yu, Y., Zhong, C., Lang, Q., Liang, Z., Lv, C., Xu, F., & Tian, Y. (2021). Long Noncoding RNA H19: A Novel Therapeutic Target Emerging in Oncology Via Regulating Oncogenic Signaling Pathways. Frontiers in Cell and Developmental Biology, 9. https://doi.org/10.3389/fcell.2021.796740
Yang, C., Zhang, J., Ma, Y., Wu, C., Cui, W., & Wang, L. (2020). Histone methyltransferase and drug resistance in cancers. Journal of Experimental & Clinical Cancer Research, 39(1), 173. https://doi.org/10.1186/s13046-020-01682-z
Yang, H., Geng, Y.-H., Wang, P., Zhang, H.-Q., Fang, W.-G., & Tian, X.-X. (2022). Extracellular ATP promotes breast cancer chemoresistance via HIF-1α signaling. Cell Death & Disease, 13(3), 199. https://doi.org/10.1038/s41419-022-04647-6
Yang, L., Kumar, B., Shen, C., Zhao, S., Blakaj, D., Li, T., Romito, M., Teknos, T. N., & Williams, T. M. (2019). LCL161, a SMAC mimetic, Preferentially Radiosensitizes Human Papillomavirus Negative Head and Neck Squamous Cell Carcinoma. Molecular Cancer Therapeutics, 18(6), 1025–1035. https://doi.org/10.1158/1535-7163.MCT-18-1157
Yang, R., Yi, M., & Xiang, B. (2022). Novel Insights on Lipid Metabolism Alterations in Drug Resistance in Cancer. Frontiers in Cell and Developmental Biology, 10. https://www.frontiersin.org/articles/10.3389/fcell.2022.875318
Yap, T. A., Daver, N., Mahendra, M., Zhang, J., Kamiya-Matsuoka, C., Meric-Bernstam, F., Kantarjian, H. M., Ravandi, F., Collins, M. E., Francesco, M. E. D., Dumbrava, E. E., Fu, S., Gao, S., Gay, J. P., Gera, S., Han, J., Hong, D. S., Jabbour, E. J., Ju, Z., … Konopleva, M. (2023). Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: Phase I trials. Nature Medicine, 29(1), 115–126. https://doi.org/10.1038/s41591-022-02103-8
Yee-Lin, V., Pooi-Fong, W., &Soo-Beng, A. K. (2018). Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment. Mini Reviews in Medicinal Chemistry, 18(2), 173–183. https://doi.org/10.2174/1389557517666170717125821
Yeldag, G., Rice, A., & del Río Hernández, A. (2018). Chemoresistance and the Self-Maintaining Tumor Microenvironment. Cancers, 10(12), 471. https://doi.org/10.3390/cancers10120471
Zhang, L., Sun, L., Wang, L., Wang, J., Wang, D., Jiang, J., Zhang, J., & Zhou, Q. (2023). Mitochondrial division inhibitor (mdivi-1) inhibits proliferation and epithelial-mesenchymal transition via the NF-κB pathway in thyroid cancer cells. Toxicology in Vitro, 88, 105552. https://doi.org/10.1016/j.tiv.2023.105552
Zhang, X., Tang, N., Hadden, T. J., & Rishi, A. K. (2011). Akt, FoxO and regulation of apoptosis. Biochimica Et BiophysicaActa, 1813(11), 1978–1986. https://doi.org/10.1016/j.bbamcr.2011.03.010
Zhang, Z.-W., Zhao, X.-S., Guo, H., & Huang, X.-J. (2023). The role of m6A demethylase FTO in chemotherapy resistance mediating acute myeloid leukemia relapse. Cell Death Discovery, 9(1), Article 1. https://doi.org/10.1038/s41420-023-01505-y
Zhao, X., Sun, W., Puszyk, W. M., Wallet, S., Hochwald, S., Robertson, K., & Liu, C. (2017). Focal adhesion kinase inhibitor PF573228 and death receptor 5 agonist lexatumumab synergistically induce apoptosis in pancreatic carcinoma. Tumour Biology, 39(5), 1010428317699120. https://doi.org/10.1177/1010428317699120
Zhao, Z., Li, T., Sun, L., Yuan, Y., & Zhu, Y. (2023). Potential mechanisms of cancer-associated fibroblasts in therapeutic resistance. Biomedicine & Pharmacotherapy, 166, 115425. https://doi.org/10.1016/j.biopha.2023.115425
Zhu, L., Zhu, Y., Li, F., Meng, Y., Wang, H., Xu, W., Luo, J., Wang, X., Feng, L., & Jin, H. (2023). RNautophagic regulation of DNMT3a‐dependent DNA methylation by Linc00942 enhances chemoresistance in gastric cancer. Clinical and Translational Medicine, 13(7), e1337. https://doi.org/10.1002/ctm2.1337
Zou, B., Lee, V. H. F., & Yan, H. (2018). Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis. BMC Bioinformatics, 19, 88. https://doi.org/10.1186/s12859-018-2093-6
Alfarouk, K. O., Stock, C.-M., Taylor, S., Walsh, M., Muddathir, A. K., Verduzco, D., Bashir, A. H. H., Mohammed, O. Y., Elhassan, G. O., Harguindey, S., Reshkin, S. J., Ibrahim, M. E., & Rauch, C. (2015). Resistance to cancer chemotherapy: Failure in drug response from ADME to P-gp. Cancer Cell International, 15, 71. https://doi.org/10.1186/s12935-015-0221-1
Alwahsh, M., Farhat, J., Talhouni, S., Hamadneh, L., &Hergenröder, R. (2023). Bortezomib advanced mechanisms of action in multiple myeloma, solid and liquid tumors along with its novel therapeutic applications. EXCLI Journal, 22, 146–168. https://doi.org/10.17179/excli2022-5653
Alzahrani, A. M., & Rajendran, P. (2020). The Multifarious Link between Cytochrome P450s and Cancer. Oxidative Medicine and Cellular Longevity, 2020, 3028387. https://doi.org/10.1155/2020/3028387
Angelopoulou, E., Paudel, Y. N., &Piperi, C. (2020). Critical role of HOX transcript antisense intergenic RNA (HOTAIR) in gliomas. Journal of Molecular Medicine (Berlin, Germany), 98(11), 1525–1546. https://doi.org/10.1007/s00109-020-01984-x
Artykov, A. A., Yagolovich, A. V., Dolgikh, D. A., Kirpichnikov, M. P., Trushina, D. B., & Gasparian, M. E. (2021). Death Receptors DR4 and DR5 Undergo Spontaneous and Ligand-Mediated Endocytosis and Recycling Regardless of the Sensitivity of Cancer Cells to TRAIL. Frontiers in Cell and Developmental Biology, 9. https://www.frontiersin.org/articles/10.3389/fcell.2021.733688
Ashino, T., Nakamura, Y., Ohtaki, H., Iwakura, Y., &Numazawa, S. (2023). Interleukin-6 regulates the expression of hepatic canalicular efflux drug transporters after cecal ligation and puncture-induced sepsis: A comparison with lipopolysaccharide treatment. Toxicology Letters, 374, 40–47. https://doi.org/10.1016/j.toxlet.2022.12.003
Audia, J. E., & Campbell, R. M. (2016). Histone Modifications and Cancer. Cold Spring Harbor Perspectives in Biology, 8(4), a019521. https://doi.org/10.1101/cshperspect.a019521
Bahar, E., Han, S.-Y., Kim, J.-Y., & Yoon, H. (2022). Chemotherapy Resistance: Role of Mitochondrial and Autophagic Components. Cancers, 14(6), 1462. https://doi.org/10.3390/cancers14061462
Bahar, M. E., Kim, H. J., & Kim, D. R. (2023). Targeting the RAS/RAF/MAPK pathway for cancer therapy: From mechanism to clinical studies. Signal Transduction and Targeted Therapy, 8(1), 455. https://doi.org/10.1038/s41392-023-01705-z
Barboza, L. G. A., Dick Vethaak, A., Lavorante, B. R. B. O., Lundebye, A.-K., & Guilhermino, L. (2018). Marine microplastic debris: An emerging issue for food security, food safety and human health. Marine Pollution Bulletin, 133, 336–348. https://doi.org/10.1016/j.marpolbul.2018.05.047
Baxter, A. A., Lay, F. T., Poon, I. K. H., Kvansakul, M., & Hulett, M. D. (2017). Tumor cell membrane-targeting cationic antimicrobial peptides: Novel insights into mechanisms of action and therapeutic prospects. Cellular and Molecular Life Sciences: CMLS, 74(20), 3809–3825. https://doi.org/10.1007/s00018-017-2604-z
Berdis, A. J. (2017). Inhibiting DNA Polymerases as a Therapeutic Intervention against Cancer. Frontiers in Molecular Biosciences, 4. https://www.frontiersin.org/articles/10.3389/fmolb.2017.00078
Bertholee, D., Maring, J. G., & van Kuilenburg, A. B. P. (2017). Genotypes Affecting the Pharmacokinetics of Anticancer Drugs. Clinical Pharmacokinetics, 56(4), 317–337. https://doi.org/10.1007/s40262-016-0450-z
Bin, L., Thorburn, J., Thomas, L. R., Clark, P. E., Humphreys, R., & Thorburn, A. (2007). Tumor-derived Mutations in the TRAIL Receptor DR5 Inhibit TRAIL Signaling through the DR4 Receptor by Competing for Ligand Binding*. Journal of Biological Chemistry, 282(38), 28189–28194. https://doi.org/10.1074/jbc.M704210200
Bogdanov, A., Bogdanov, A., Chubenko, V., Volkov, N., Moiseenko, F., &Moiseyenko, V. (2022). Tumor acidity: From hallmark of cancer to target of treatment. Frontiers in Oncology, 12, 979154. https://doi.org/10.3389/fonc.2022.979154
Bou Antoun, N., &Chioni, A.-M.(2023). DysregulatedSignalling Pathways Driving Anticancer Drug Resistance. International Journal of Molecular Sciences, 24(15), 12222. https://doi.org/10.3390/ijms241512222
Brown, K. E. (2018). Revisiting CD28 Superagonist TGN1412 as Potential Therapeutic for Pediatric B Cell Leukemia: A Review. Diseases, 6(2), 41. https://doi.org/10.3390/diseases6020041
Bukowski, K., Kciuk, M., &Kontek, R. (2020).Mechanisms of Multidrug Resistance in Cancer Chemotherapy.International Journal of Molecular Sciences, 21(9), 3233.https://doi.org/10.3390/ijms21093233
Buscaglia LE, Li Y. (2011) Apoptosis and the target genes of microRNA-21. Chin J Cancer. 30(6):371-80. https://doi.org/10.5732/cjc.011.10132 .
Cadamuro, M., Brivio, S., Spirli, C., Joplin, R. E., Strazzabosco, M., & Fabris, L. (2017).Autocrine and Paracrine Mechanisms Promoting Chemoresistance in Cholangiocarcinoma. International Journal of Molecular Sciences, 18(1),149. https://doi.org/10.3390/ijms18010149
Campbell, K. J., & Leung, H. Y. (2021). Evasion of cell death: A contributory factor in prostate cancer development and treatment resistance. Cancer Letters, 520, 213–221. https://doi.org/10.1016/j.canlet.2021.07.045
Campbell, K. J., & Tait, S. W. G. (2018). Targeting BCL-2 regulated apoptosis in cancer. Open Biology, 8(5), 180002. https://doi.org/10.1098/rsob.180002
Castro-Muñoz, L. J., Vázquez Ulloa, E., Sahlgren, C., Lizano, M., De La Cruz-Hernández, E., & Contreras-Paredes, A. (2023). Modulating epigenetic modifications for cancer therapy (Review). Oncology Reports, 49(3), 59. https://doi.org/10.3892/or.2023.8496
Centurione, L., & Aiello, F. B. (2016). DNA Repair and Cytokines: TGF-β, IL-6, and Thrombopoietin as Different Biomarkers of Radioresistance. Frontiers in Oncology, 6, 175. https://doi.org/10.3389/fonc.2016.00175
Chakraborty, A. R., Robey, R. W., Luchenko, V. L., Zhan, Z., Piekarz, R. L., Gillet, J.-P., Kossenkov, A. V., Wilkerson, J., Showe, L. C., Gottesman, M. M., Collie, N. L., & Bates, S. E. (2013). MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: Rationale to combine romidepsin with an MEK inhibitor. Blood, 121(20), 4115–4125. https://doi.org/10.1182/blood-2012-08-449140
Chan, L. M. S., Lowes, S., & Hirst, B. H. (2004). The ABCs of drug transport in intestine and liver: Efflux proteins limiting drug absorption and bioavailability. European Journal of Pharmaceutical Sciences, 21(1), 25–51. https://doi.org/10.1016/j.ejps.2003.07.003
Chandrasekhar, C., Kumar, P. S., & Sarma, P. V. G. K. (2019). Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients. Scientific Reports, 9(1), Article 1. https://doi.org/10.1038/s41598-019-38672-x
Characteristics of the cancer stem cell niche and therapeutic strategies | Stem Cell Research & Therapy | Full Text.(n.d.). Retrieved February 17, 2024, from https://stemcellres.biomedcentral.com/articles/10.1186/s13287-022-02904-1
Chen, J.-J., Shen, H.-C.J., Rivera Rosado, L. A., Zhang, Y., Di, X., & Zhang, B. (2012). Mislocalization of death receptors correlates with cellular resistance to their cognate ligands in human breast cancer cells. Oncotarget, 3(8), 833–842. https://doi.org/10.18632/oncotarget.542
Chen, L., Zeng, Y., Zhou, S.-F., Chen, L., Zeng, Y., & Zhou, S.-F.(2018). Role of Apoptosis in Cancer Resistance to Chemotherapy. In Current Understanding of Apoptosis—Programmed Cell Death. In tech. https://doi.org/10.5772/intechopen.80056
Chibaya, L., Karim, B., Zhang, H., & Jones, S. N. (2021). Mdm2 phosphorylation by Akt regulates the p53 response to oxidative stress to promote cell proliferation and tumorigenesis. Proceedings of the National Academy of Sciences, 118(4), e2003193118. https://doi.org/10.1073/pnas.2003193118
Chota, A., George, B. P., & Abrahamse, H. (2021). Interactions of multidomain pro-apoptotic and anti-apoptotic proteins in cancer cell death. Oncotarget, 12(16), 1615–1626. https://doi.org/10.18632/oncotarget.28031
Chu, S., &Stochaj, U. (2020).Exploring near-infrared absorbing nanocarriers to overcome cancer drug resistance. Cancer Drug Resistance, 3(3), 302–333. https://doi.org/10.20517/cdr.2020.20
Comandatore, A., Immordino, B., Balsano, R., Capula, M., Garajovà, I., Ciccolini, J., Giovannetti, E., & Morelli, L. (2022).Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer. Diagnostics, 12(2), 286. https://doi.org/10.3390/diagnostics12020286
Cournoyer, S., Addioui, A., Belounis, A., Beaunoyer, M., Nyalendo, C., Le Gall, R., Teira, P., Haddad, E., Vassal, G., &Sartelet, H. (2019). GX15–070 (Obatoclax), a Bcl-2 family proteins inhibitor engenders apoptosis and pro-survival autophagy and increases Chemosensitivity in neuroblastoma. BMC Cancer, 19(1), 1018. https://doi.org/10.1186/s12885-019-6195-y
D’Aguanno, S., & Del Bufalo, D. (2020). Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer. Cells, 9(5), 1287. https://doi.org/10.3390/cells9051287
D’Alterio, C., Scala, S., Sozzi, G., Roz, L., & Bertolini, G. (2020).Paradoxical effects of chemotherapy on tumor relapse and metastasis promotion. Seminars in Cancer Biology, 60, 351–361. https://doi.org/10.1016/j.semcancer.2019.08.019
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997). Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery. Cell, 91(2), 231–241. https://doi.org/10.1016/S0092-8674(00)80405-5
de la Cruz-López, K. G., Castro-Muñoz, L. J., Reyes-Hernández, D. O., García-Carrancá, A., & Manzo-Merino, J. (2019). Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches. Frontiers in Oncology, 9, 1143. https://doi.org/10.3389/fonc.2019.01143
de la Torre, B. G., &Albericio, F. (2023). The Pharmaceutical Industry in 2022: An Analysis of FDA Drug Approvals from the Perspective of Molecules. Molecules, 28(3), 1038. https://doi.org/10.3390/molecules28031038
De Zio, D., Cianfanelli, V., & Cecconi, F. (2013). New Insights into the Link Between DNA Damage and Apoptosis. Antioxidants & Redox Signaling, 19(6), 559–571. https://doi.org/10.1089/ars.2012.4938
Delou, J. M. A., Souza, A. S. O., Souza, L. C. M., & Borges, H. L. (2019). Highlights in Resistance Mechanism Pathways for Combination Therapy. Cells, 8(9), 1013. https://doi.org/10.3390/cells8091013
Devanaboyina, M., Kaur, J., Whiteley, E., Lin, L., Einloth, K., Morand, S., Stanbery, L., Hamouda, D., & Nemunaitis, J. (2022). NF-κBSignaling in Tumor Pathways Focusing on Breast and Ovarian Cancer. Oncology Reviews, 16, 10568. https://doi.org/10.3389/or.2022.10568
Dine, J. L., O’Sullivan, C. C., Voeller, D., Greer, Y. E., Chavez, K. J., Conway, C. M., Sinclair, S., Stone, B., Amiri-Kordestani, L., Merchant, A. S., Hewitt, S. M., Steinberg, S. M., Swain, S. M., & Lipkowitz, S. (2016). The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. Breast Cancer Research and Treatment, 155(2), 235–251. https://doi.org/10.1007/s10549-015-3673-z
Dong, C., Wu, J., Chen, Y., Nie, J., & Chen, C. (2021). Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer. Frontiers in Pharmacology, 12, 628690. https://doi.org/10.3389/fphar.2021.628690
Du, Z., &Lovly, C. M. (2018).Mechanisms of receptor tyrosine kinase activation in cancer. Molecular Cancer, 17(1), 58. https://doi.org/10.1186/s12943-018-0782-4
Emran, T. B., Shahriar, A., Mahmud, A. R., Rahman, T., Abir, M. H., Siddiquee, Mohd. F.-R., Ahmed, H., Rahman, N., Nainu, F., Wahyudin, E., Mitra, S., Dhama, K., Habiballah, M. M., Haque, S., Islam, A., & Hassan, M. M. (2022). Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches. Frontiers in Oncology, 12. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.891652
Engle, K., & Kumar, G. (2022). Cancer multidrug-resistance reversal by ABCB1 inhibition: A recent update. European Journal of Medicinal Chemistry, 239, 114542. https://doi.org/10.1016/j.ejmech.2022.114542
Ferris, R. L., Harrington, K., Schoenfeld, J. D., Tahara, M., Esdar, C., Salmio, S., Schroeder, A., &Bourhis, J. (2023).Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck. Cancer Treatment Reviews, 113. https://doi.org/10.1016/j.ctrv.2022.102492
Gagnon, V., Van Themsche, C., Turner, S., Leblanc, V., & Asselin, E. (2008). Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol. Apoptosis: An International Journal on Programmed Cell Death, 13(2), 259–271. https://doi.org/10.1007/s10495-007-0165-6
Gao, P., Bauvy, C., Souquère, S., Tonelli, G., Liu, L., Zhu, Y., Qiao, Z., Bakula, D., Proikas-Cezanne, T., Pierron, G., Codogno, P., Chen, Q., &Mehrpour, M. (2010). The Bcl-2 Homology Domain 3 Mimetic Gossypol Induces Both Beclin 1-dependent and Beclin 1-independent Cytoprotective Autophagy in Cancer Cells. The Journal of Biological Chemistry, 285(33), 25570–25581. https://doi.org/10.1074/jbc.M110.118125
Giacomini, C., Granéli, C., Hicks, R., & Dazzi, F. (2023). The critical role of apoptosis in mesenchymal stromal cell therapeutics and implications in homeostasis and normal tissue repair. Cellular & Molecular Immunology, 20(6), Article 6. https://doi.org/10.1038/s41423-023-01018-9
Gluck, W. L., Gounder, M. M., Frank, R., Eskens, F., Blay, J. Y., Cassier, P. A., Soria, J.-C., Chawla, S., de Weger, V., Wagner, A. J., Siegel, D., De Vos, F., Rasmussen, E., &Henary, H. A. (2020). Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma. Investigational New Drugs, 38(3), 831–843. https://doi.org/10.1007/s10637-019-00840-1
Godwin, I., Anto, N. P., Bava, S. V., Babu, M. S., & Jinesh, G. G. (2021).Targeting K-Ras and apoptosis-driven cellular transformation in cancer. Cell Death Discovery, 7, 80. https://doi.org/10.1038/s41420-021-00457-5
Gouju, J., &Legeay, S. (2023). Pharmacokinetics of obese adults: Not only an increase in weight. Biomedicine & Pharmacotherapy, 166, 115281. https://doi.org/10.1016/j.biopha.2023.115281
Groen, K., van de Donk, N., Stege, C., Zweegman, S., &Nijhof, I. (2019).Carfilzomib for relapsed and refractory multiple myeloma. Cancer Management and Research, 11, 2663–2675. https://doi.org/10.2147/CMAR.S150653
Guan, Y., Wang, Y., Li, B., Shen, K., Li, Q., Ni, Y., & Huang, L. (2021).Mitophagy in carcinogenesis, drug resistance and anticancer therapeutics. Cancer Cell International, 21, 350. https://doi.org/10.1186/s12935-021-02065-w
Guo, M., Peng, Y., Gao, A., Du, C., & Herman, J. G. (2019). Epigenetic heterogeneity in cancer. Biomarker Research, 7(1), 23. https://doi.org/10.1186/s40364-019-0174-y
Han, W., Shi, L., Ren, L., Zhou, L., Li, T., Qiao, Y., & Wang, H. (2018). A nanomedicine approach enables co-delivery of cyclosporin A and gefitinib to potentiate the therapeutic efficacy in drug-resistant lung cancer. Signal Transduction and Targeted Therapy, 3(1), Article 1. https://doi.org/10.1038/s41392-018-0019-4
Hanahan, D. (2022). Hallmarks of Cancer: New Dimensions. Cancer Discovery, 12(1), 31–46. https://doi.org/10.1158/2159-8290.CD-21-1059
Hassanin, I., & Elzoghby, A. (2020). Albumin-based nanoparticles: A promising strategy to overcome cancer drug resistance. Cancer Drug Resistance, 3(4), 930–946. https://doi.org/10.20517/cdr.2020.68
Hasty, P., & Montagna, C. (2014). Chromosomal rearrangements in cancer. Molecular & Cellular Oncology, 1(1), e29904. https://doi.org/10.4161/mco.29904
He, X., Yan, Q., Kuang, G., Wang, Y., Cao, P., & Ou, C. (2018). Metastasis-associated lung adenocarcinoma transcript 1 regulates tumor progression: Old wine in a new bottle. Journal of Thoracic Disease, 10(Suppl 9), S1088–S1091. https://doi.org/10.21037/jtd.2018.04.13
Henke, E., Nandigama, R., & Ergün, S. (2020). Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy. Frontiers in Molecular Biosciences, 6, 160. https://doi.org/10.3389/fmolb.2019.00160
Hoeben, A., Joosten, E. A. J., & van den Beuken-van Everdingen, M. H. J. (2021).Personalized Medicine: Recent Progress in Cancer Therapy. Cancers, 13(2), 242. https://doi.org/10.3390/cancers13020242
Hu, J., Jing, H., & Lin, H. (2014). Sirtuin inhibitors as anticancer agents. Future Medicinal Chemistry, 6(8), 945–966. https://doi.org/10.4155/fmc.14.44
Hu, X., & Chen, W. (2021).Role of epithelial-mesenchymal transition in chemoresistance in pancreatic ductal adenocarcinoma. World Journal of Clinical Cases, 9(19), 4998–5006. https://doi.org/10.12998/wjcc.v9.i19.4998
Hu, Y., Yagüe, E., Zhao, J., Wang, L., Bai, J., Yang, Q., Pan, T., Zhao, H., Liu, J., & Zhang, J. (2018).Sabutoclax, pan-active BCL-2 protein family antagonist, overcomes drug resistance and eliminates cancer stem cells in breast cancer. Cancer Letters, 423, 47–59. https://doi.org/10.1016/j.canlet.2018.02.036
Huang, Y., Sun, G., Sun, X., Li, F., Zhao, L., Zhong, R., & Peng, Y. (2020). The Potential of Lonidamine in Combination with Chemotherapy and Physical Therapy in Cancer Treatment. Cancers, 12(11), 3332. https://doi.org/10.3390/cancers12113332
Icard, P., Shulman, S., Farhat, D., Steyaert, J.-M., Alifano, M., &Lincet, H. (2018). How the Warburg effect supports aggressiveness and drug resistance of cancer cells? Drug Resistance Updates, 38, 1–11. https://doi.org/10.1016/j.drup.2018.03.001
Janzer, A., German, N. J., Gonzalez-Herrera, K. N., Asara, J. M., Haigis, M. C., &Struhl, K. (2014). Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells. Proceedings of the National Academy of Sciences, 111(29), 10574–10579. https://doi.org/10.1073/pnas.1409844111
Je, H., Nam, G.-H., Kim, G. B., Kim, W., Kim, S. R., Kim, I.-S., & Lee, E. J. (2021).Overcoming therapeutic efficiency limitations against TRAIL-resistant tumors using re-sensitizing agent-loaded trimeric TRAIL-presenting nanocages. Journal of Controlled Release, 331, 7–18. https://doi.org/10.1016/j.jconrel.2021.01.016
Jeena, M. T., Kim, S., Jin, S., & Ryu, J.-H. (2019). Recent Progress in Mitochondria-Targeted Drug and Drug-Free Agents for Cancer Therapy. Cancers, 12(1), 4. https://doi.org/10.3390/cancers12010004
Jeong, S.-J., Dasgupta, A., Jung, K.-J., Um, J.-H., Burke, A., Park, H. U., & Brady, J. N. (2008). PI3K/AKT inhibition induces caspase-dependent apoptosis in HTLV-1 transformed cells. Virology, 370(2), 264–272. https://doi.org/10.1016/j.virol.2007.09.003
Jia, L.-T., Chen, S.-Y., & Yang, A.-G.(2012). Cancer gene therapy targeting cellular apoptosis machinery. Cancer Treatment Reviews, 38(7), 868–876. https://doi.org/10.1016/j.ctrv.2012.06.008
Jiang, G., Deng, W., Liu, Y., & Wang, C. (2020). General mechanism of JQ1 in inhibiting various types of cancer. Molecular Medicine Reports, 21(3), 1021–1034. https://doi.org/10.3892/mmr.2020.10927
Jim Yen, M., Shih, I.-M., Velculescu, V. E., & Wang, T.-L. (2006). Amplification in DNA Copy Numbers as a Mechanism of Acquired Drug Resistance. In B. A. Teicher (Ed.), Cancer Drug Resistance (pp. 531–540). Humana Press. https://doi.org/10.1007/978-1-59745-035-5_28
Jones, V. S., Huang, R.-Y., Chen, L.-P., Chen, Z.-S., Fu, L., & Huang, R.-P. (2016). Cytokines in cancer drug resistance: Cues to new therapeutic strategies. BiochimicaetBiophysicaActa (BBA) - Reviews on Cancer, 1865(2), 255–265. https://doi.org/10.1016/j.bbcan.2016.03.005
Joshi, R. S., Kanugula, S. S., Sudhir, S., Pereira, M. P., Jain, S., & Aghi, M. K. (2021). The Role of Cancer-Associated Fibroblasts in Tumor Progression. Cancers, 13(6), 1399. https://doi.org/10.3390/cancers13061399
Jurkovicova, D., Neophytou, C. M., Gašparović, A. Č., & Gonçalves, A. C. (2022). DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities. International Journal of Molecular Sciences, 23(23), 14672. https://doi.org/10.3390/ijms232314672
Karthika, C., Sureshkumar, R., Zehravi, M., Akter, R., Ali, F., Ramproshad, S., Mondal, B., Tagde, P., Ahmed, Z., Khan, F. S., Rahman, M. H., &Cavalu, S. (2022). Multidrug Resistance of Cancer Cells and the Vital Role of P-Glycoprotein. Life, 12(6), Article 6. https://doi.org/10.3390/life12060897
Kartikasari, A. E. R., Huertas, C. S., Mitchell, A., & Plebanski, M. (2021).Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis. Frontiers in Oncology, 11. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.692142
Kashiwagi, H., McDunn, J. E., Goedegebuure, P. S., Gaffney, M. C., Chang, K., Trinkaus, K., Piwnica-Worms, D., Hotchkiss, R. S., & Hawkins, W. G. (2007). TAT-Bim induces extensive apoptosis in cancer cells. Annals of Surgical Oncology, 14(5), 1763–1771. https://doi.org/10.1245/s10434-006-9298-z
Ko, Y. T., Falcao, C., &Torchilin, V. P. (2009). Cationic liposomes loaded with pro-apoptotic peptide D-(KLAKLAK)2 and bcl-2 antisense oligodeoxynucleotide G3139 for enhanced anti-cancer therapy. Molecular Pharmaceutics, 6(3), 971–977. https://doi.org/10.1021/mp900006h
Konopleva, M. Y., Röllig, C., Cavenagh, J., Deeren, D., Girshova, L., Krauter, J., Martinelli, G., Montesinos, P., Schäfer, J. A., Ottmann, O., Petrini, M., Pigneux, A., Rambaldi, A., Recher, C., Rodriguez-Veiga, R., Taussig, D., Vey, N., Yoon, S.-S., Ott, M., … Wei, A. H. (2022). Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: Results of the MIRROS trial. Blood Advances, 6(14), 4147–4156. https://doi.org/10.1182/bloodadvances.2021006303
Kozlova, N., Grossman, J. E., Iwanicki, M. P., & Muranen, T. (2020).The interplay of the extracellular matrix and stromal cells as a drug target in stroma-rich cancers. Trends in Pharmacological Sciences, 41(3), 183–198. https://doi.org/10.1016/j.tips.2020.01.001
Krendyukov, A., &Gieffers, C. (2019). Asunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignancies. Cancer Management and Research, 11, 8095. https://doi.org/10.2147/CMAR.S216675
Kumar, S., Kushwaha, P. P., & Gupta, S. (2019). Emerging targets in cancer drug resistance. Cancer Drug Resistance, 2(2), 161–177. https://doi.org/10.20517/cdr.2018.27
Lakshminarasimhan, R., & Liang, G. (2016).The Role of DNA Methylation in Cancer. Advances in Experimental Medicine and Biology, 945, 151–172. https://doi.org/10.1007/978-3-319-43624-1_7
Lathia, J. D., Mack, S. C., Mulkearns-Hubert, E. E., Valentim, C. L. L., & Rich, J. N. (2015). Cancer stem cells in glioblastoma. Genes & Development, 29(12), 1203–1217. https://doi.org/10.1101/gad.261982.115
Lee, S. H., Shin, M. S., Kim, H. S., Lee, H. K., Park, W. S., Kim, S. Y., Lee, J. H., Han, S. Y., Park, J. Y., Oh, R. R., Jang, J. J., Han, J. Y., Lee, J. Y., & Yoo, N. J. (1999). Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer research, 59(22), 5683–5686.
Lee, S., Rauch, J., &Kolch, W. (2020).Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity.International Journal of Molecular Sciences, 21(3), 1102. https://doi.org/10.3390/ijms21031102
Leeuwen, R. W. F. van, Jansman, F. G. A., Bemt, P. M. L. A. van den, Man, F. de, Piran, F., Vincenten, I., Jager, A., Rijneveld, A. W., Brugma, J. D., Mathijssen, R. H. J., & Gelder, T. van. (2015). Drug–drug interactions in patients treated for cancer: A prospective study on clinical interventions. Annals of Oncology, 26(5), 992–997. https://doi.org/10.1093/annonc/mdv029
Lei, W., Duan, R., Li, J., Liu, X., Huston, A., Boyce, B. F., & Yao, Z. (2020). The IAP Antagonist SM-164 Eliminates Triple-Negative Breast Cancer Metastasis to Bone and Lung in Mice. Scientific Reports, 10(1), 7004. https://doi.org/10.1038/s41598-020-64018-z
Li, H.-J., Gong, X., Li, Z.-K., Qin, W., He, C.-X., Xing, L., Zhou, X., Zhao, D., & Cao, H.-L. (2021). Role of Long Non-coding RNAs on Bladder Cancer. Frontiers in Cell and Developmental Biology, 9, 672679. https://doi.org/10.3389/fcell.2021.672679
Li, X., Qiu, Z., Jin, Q., Chen, G., & Guo, M. (2018). Cell Cycle Arrest and Apoptosis in HT-29 Cells Induced by Dichloromethane Fraction From Toddalia asiatica (L.) Lam. Frontiers in Pharmacology, 9. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.00629
Lim, B., Greer, Y., Lipkowitz, S., & Takebe, N. (2019). Novel Apoptosis-Inducing Agents for the Treatment of Cancer, a New Arsenal in the Toolbox. Cancers, 11(8), 1087. https://doi.org/10.3390/cancers11081087
Lin, J. H., & Yamazaki, M. (2003). Role of P-glycoprotein in pharmacokinetics: Clinical implications. Clinical Pharmacokinetics, 42(1), 59–98. https://doi.org/10.2165/00003088-200342010-00003
Lin, J., Song, T., Li, C., & Mao, W. (2020). GSK-3β in DNA repair, apoptosis, and resistance of chemotherapy, radiotherapy of cancer. Biochimicaet Biophysica Acta (BBA) - Molecular Cell Research, 1867(5), 118659. https://doi.org/10.1016/j.bbamcr.2020.118659
Lin, X., Xiao, Z., Chen, T., Liang, S. H., & Guo, H. (2020).Glucose Metabolism on Tumor Plasticity, Diagnosis, and Treatment. Frontiers in Oncology, 10, 317. https://doi.org/10.3389/fonc.2020.00317
Liu, G., Chen, T., Zhang, X., Ma, X., & Shi, H. (2022).Small molecule inhibitors targeting the cancers. Med Comm, 3(4), e181. https://doi.org/10.1002/mco2.181
Liu, K., Gao, L., Ma, X., Huang, J.-J., Chen, J., Zeng, L., Ashby, C. R., Zou, C., & Chen, Z.-S. (2020). Long non-coding RNAs regulate drug resistance in cancer. Molecular Cancer, 19, 54. https://doi.org/10.1186/s12943-020-01162-0
Liu, R., Chen, Y., Liu, G., Li, C., Song, Y., Cao, Z., Li, W., Hu, J., Lu, C., & Liu, Y. (2020). PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death & Disease, 11(9), Article 9. https://doi.org/10.1038/s41419-020-02998-6
Liu, Y., Zhang, H., Cui, H., Zhang, F., Zhao, L., Liu, Y., & Meng, Q. (2022). Combined and targeted drugs delivery system for colorectal cancer treatment: Conatumumab decorated, reactive oxygen species sensitive irinotecan prodrug and quercetin co-loaded nanostructured lipid carriers. Drug Delivery, 29(1), 342–350. https://doi.org/10.1080/10717544.2022.2027573
Lønning, P. E., & Knappskog, S. (2013). Mapping genetic alterations causing chemoresistance in cancer: Identifying the roads by tracking the drivers. Oncogene, 32(46), Article 46. https://doi.org/10.1038/onc.2013.48
Luo, Z.-D., Wang, Y.-F., Zhao, Y.-X., Yu, L.-C., Li, T., Fan, Y.-J., Zeng, S.-J., Zhang, Y.-L., Zhang, Y., & Zhang, X. (2023).Emerging roles of non-coding RNAs in colorectal cancer oxaliplatin resistance and liquid biopsy potential. World Journal of Gastroenterology, 29(1), 1–18. https://doi.org/10.3748/wjg.v29.i1.1
Magee, P., Shi, L., & Garofalo, M. (2015).Role of microRNAs in chemoresistance. Annals of Translational Medicine, 3(21), 332. https://doi.org/10.3978/j.issn.2305-5839.2015.11.32
Mahgoub, E. O., Cho, W. C., Sharifi, M., Falahati, M., Zeinabad, H. A., Mare, H. E., & Hasan, A. (2024).Role of functional genomics in identifying cancer drug resistance and overcoming cancer relapse. Heliyon, 10(1), e22095. https://doi.org/10.1016/j.heliyon.2023.e22095
Malla, W. A., Arora, R., Khan, R. I. N., Mahajan, S., & Tiwari, A. K. (2020). Apoptin as a Tumor-Specific Therapeutic Agent: Current Perspective on Mechanism of Action and Delivery Systems. Frontiers in Cell and Developmental Biology, 8, 524. https://doi.org/10.3389/fcell.2020.00524
Marusyk, A., Janiszewska, M., & Polyak, K. (2020). Intratumor heterogeneity: The Rosetta stone of therapy resistance. Cancer Cell, 37(4), 471–484. https://doi.org/10.1016/j.ccell.2020.03.007
Matsui, A., Ihara, T., Suda, H., Mikami, H., & Semba, K. (2013). Gene amplification: Mechanisms and involvement in cancer. BioMolecular Concepts, 4(6), 567–582. https://doi.org/10.1515/bmc-2013-0026
Matuszewska, K., Pereira, M., Petrik, D., Lawler, J., & Petrik, J. (2021). Normalizing Tumor Vasculature to Reduce Hypoxia, Enhance Perfusion, and Optimize Therapy Uptake. Cancers, 13(17), 4444. https://doi.org/10.3390/cancers13174444
Mechanisms of acquired tumor drug resistance. (2019). Biochimicaet Biophysica Acta (BBA) - Reviews on Cancer, 1872(2), 188310. https://doi.org/10.1016/j.bbcan.2019.188310
Meng, C.-Y., Zhao, Z.-Q., Bai, R., Zhao, W., Wang, Y.-X., Sun, L., Sun, C., Feng, W., & Guo, S.-B. (2020). MicroRNA-22 regulates autophagy and apoptosis in cisplatin resistance of osteosarcoma. Molecular Medicine Reports, 22(5), 3911–3921. https://doi.org/10.3892/mmr.2020.11447
MengieAyele, T., Tilahun Muche, Z., BehaileTeklemariam, A., Bogale Kassie, A., &ChekolAbebe, E. (2022). Role of JAK2/STAT3 Signaling Pathway in the Tumorigenesis, Chemotherapy Resistance, and Treatment of Solid Tumors: A Systemic Review. Journal of Inflammation Research, 15, 1349–1364. https://doi.org/10.2147/JIR.S353489
Mohammad, R. M., Muqbil, I., Lowe, L., Yedjou, C., Hsu, H.-Y., Lin, L.-T., Siegelin, M. D., Fimognari, C., Kumar, N. B., Dou, Q. P., Yang, H., Samadi, A. K., Russo, G. L., Spagnuolo, C., Ray, S. K., Chakrabarti, M., Morre, J. D., Coley, H. M., Honoki, K., … Azmi, A. S. (2015). Broad targeting of resistance to apoptosis in cancer. Seminars in Cancer Biology, 35, S78–S103. https://doi.org/10.1016/j.semcancer.2015.03.001
Muz, B., Ghazarian, R. N., Ou, M., Luderer, M. J., Kusdono, H. D., & Azab, A. K. (2016).Spotlight on ixazomib: Potential in the treatment of multiple myeloma. Drug Design, Development and Therapy, 10, 217–226. https://doi.org/10.2147/DDDT.S93602
Nanayakkara, A. K., Follit, C. A., Chen, G., Williams, N. S., Vogel, P. D., & Wise, J. G. (2018). Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells. Scientific Reports, 8(1), 967. https://doi.org/10.1038/s41598-018-19325-x
Neophytou, C. M., Trougakos, I. P., Erin, N., &Papageorgis, P. (2021).Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance. Cancers, 13(17), Article 17. https://doi.org/10.3390/cancers13174363
Nishikawa, S., & Iwakuma, T. (2023). Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials. Cancers, 15(2), 429. https://doi.org/10.3390/cancers15020429
Nor Hisam, N. S., Ugusman, A., Rajab, N. F., Ahmad, M. F., Fenech, M., Liew, S. L., & Mohamad Anuar, N. N. (2021). Combination Therapy of Navitoclax with Chemotherapeutic Agents in Solid Tumors and Blood Cancer: A Review of Current Evidence. Pharmaceutics, 13(9), 1353. https://doi.org/10.3390/pharmaceutics13091353
Novikov, N. M., Zolotaryova, S. Y., Gautreau, A. M., & Denisov, E. V. (2021). Mutational drivers of cancer cell migration and invasion. British Journal of Cancer, 124(1), Article 1. https://doi.org/10.1038/s41416-020-01149-0
Nussinov, R., Tsai, C.-J., & Jang, H. (2017).A New View of Pathway-Driven Drug Resistance in Tumor Proliferation. Trends in Pharmacological Sciences, 38(5), 427–437. https://doi.org/10.1016/j.tips.2017.02.001
Ozcan, G. (2023). The hypoxia-inducible factor-1α in stemness and resistance to chemotherapy in gastric cancer: Future directions for therapeutic targeting. Frontiers in Cell and Developmental Biology, 11, 1082057. https://doi.org/10.3389/fcell.2023.1082057
Palamaris, K., Felekouras, E., & Sakellariou, S. (2021). Epithelial to Mesenchymal Transition: Key Regulator of Pancreatic Ductal Adenocarcinoma Progression and Chemoresistance. Cancers, 13(21), 5532. https://doi.org/10.3390/cancers13215532
Papadopoulou, A., Govina, O., Tsatsou, I., Mantzorou, M., Mantoudi, A., Tsiou, C., &Adamakidou, T. (2022).Quality of life, distress, anxiety and depression of ambulatory cancer patients receiving chemotherapy. Medicine and Pharmacy Reports, 95(4), 418–429. https://doi.org/10.15386/mpr-2458
Patel, A. B., O’Hare, T., & Deininger, M. W. (2017).Mechanisms of resistance to ABL kinase inhibition in CML and the development of next generation ABL kinase inhibitors. Hematology/Oncology Clinics of North America, 31(4), 589–612. https://doi.org/10.1016/j.hoc.2017.04.007
Pathak, S., Singh, V., Kumar, N., &Jayandharan, G. R. (2023). Inducible caspase 9-mediated suicide gene therapy using AAV6 vectors in a murine model of breast cancer. Molecular Therapy Methods & Clinical Development, 31. https://doi.org/10.1016/j.omtm.2023.101166
Pavlíková, L., Šereš, M., Breier, A., &Sulová, Z. (2022).The Roles of microRNAs in Cancer Multidrug Resistance. Cancers, 14(4), 1090. https://doi.org/10.3390/cancers14041090
Pekarsky, Y., Balatti, V., & Croce, C. M. (2018). BCL2 and miR-15/16: From gene discovery to treatment. Cell Death & Differentiation, 25(1), Article 1. https://doi.org/10.1038/cdd.2017.159
Pfeffer, C. M., & Singh, A. T. K. (2018). Apoptosis: A Target for Anticancer Therapy. International Journal of Molecular Sciences, 19(2), 448. https://doi.org/10.3390/ijms19020448
Phi, L. T. H., Sari, I. N., Yang, Y.-G., Lee, S.-H., Jun, N., Kim, K. S., Lee, Y. K., & Kwon, H. Y. (2018). Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment. Stem Cells International, 2018, 5416923. https://doi.org/10.1155/2018/5416923
Pojani, E., & Barlocco, D. (2021).Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy. Current Medicinal Chemistry, 28(7), 1290–1303. https://doi.org/10.2174/0929867327666200203113926
Pote, M. S., & Gacche, R. N. (2023).ATP-binding cassette efflux transporters and MDR in cancer. Drug Discovery Today, 28(5), 103537. https://doi.org/10.1016/j.drudis.2023.103537
Qian, S., Wei, Z., Yang, W., Huang, J., Yang, Y., & Wang, J. (2022).The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. Frontiers in Oncology, 12, 985363. https://doi.org/10.3389/fonc.2022.985363
Rahman, H., Rudrow, A., Carneglia, J., Joly, S. S. P., Nicotera, D., Naldrett, M., Choy, J., Ambudkar, S. V., & Golin, J. (2020). Nonsynonymous Mutations in Linker-2 of the Pdr5 Multidrug Transporter Identify a New RNA Stability Element. G3 (Bethesda, Md.), 10(1), 357–369. https://doi.org/10.1534/g3.119.400863
Rajan, P. K., Udoh, U.-A., Sanabria, J. D., Banerjee, M., Smith, G., Schade, M. S., Sanabria, J., Sodhi, K., Pierre, S., Xie, Z., Shapiro, J. I., & Sanabria, J. (2020). The Role of Histone Acetylation-/Methylation-Mediated Apoptotic Gene Regulation in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 21(23), 8894. https://doi.org/10.3390/ijms21238894
Ramadhani, D., Maharani, R., Gazzali, A. M., & Muchtaridi, M. (2022). Cyclic Peptides for the Treatment of Cancers: A Review. Molecules, 27(14), 4428. https://doi.org/10.3390/molecules27144428
Rangel, L. P., Ferretti, G. D. S., Costa, C. L., Andrade, S. M. M. V., Carvalho, R. S., Costa, D. C. F., & Silva, J. L. (2019). P53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells. The Journal of Biological Chemistry, 294(10), 3670–3682. https://doi.org/10.1074/jbc.RA118.004671
Regulated cell death (RCD) in cancer: Key pathways and targeted therapies | Signal Transduction and Targeted Therapy. (n.d.). Retrieved February 18, 2024, from https://www.nature.com/articles/s41392-022-01110-y
Ren, L., & Yu, Y. (2018).The role of miRNAs in the diagnosis, chemoresistance, and prognosis of pancreatic ductal adenocarcinoma. Therapeutics and Clinical Risk Management, 14, 179–187. https://doi.org/10.2147/TCRM.S154226
Rieger, C., Huebner, D., Temme, A., Wirth, M. P., & Fuessel, S. (2015). Antisense- and siRNA-mediated inhibition of the anti-apoptotic gene Bcl-xL for chemosensitization of bladder cancer cells. International Journal of Oncology, 47(3), 1121–1130. https://doi.org/10.3892/ijo.2015.3096
Roberts, A. W., Wei, A. H., & Huang, D. C. S. (2021).BCL2 and MCL1 inhibitors for hematologic malignancies. Blood, 138(13), 1120–1136. https://doi.org/10.1182/blood.2020006785
Roberts, J. A., Pea, F., & Lipman, J. (2013).The Clinical Relevance of Plasma Protein Binding Changes. Clinical Pharmacokinetics, 52(1), 1–8. https://doi.org/10.1007/s40262-012-0018-5
Robey, R. W., Pluchino, K. M., Hall, M. D., Fojo, A. T., Bates, S. E., & Gottesman, M. M. (2018).Revisiting the role of efflux pumps in multidrug-resistant cancer. Nature Reviews Cancer, 18(7), 452–464. https://doi.org/10.1038/s41568-018-0005-8
Roth, C., Pantel, K., Müller, V., Rack, B., Kasimir-Bauer, S., Janni, W., & Schwarzenbach, H. (2011). Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression. BMC Cancer, 11(1), 4. https://doi.org/10.1186/1471-2407-11-4
Rudzińska, M., Daglioglu, C., Savvateeva, L. V., Kaci, F. N., Antoine, R., &ZamyatninJr, A. A. (2021). Current Status and Perspectives of Protease Inhibitors and Their Combination with Nanosized Drug Delivery Systems for Targeted Cancer Therapy. Drug Design Development and Therapy, 15, 9–20. https://doi.org/10.2147/DDDT.S285852
Sano, R., & Reed, J. C. (2013). ER stress-induced cell death mechanisms. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, 1833(12), 3460-3470.. https://doi.org/10.1016/j.bbamcr.2013.06.028
Segal, E. M., Flood, M. R., Mancini, R. S., Whiteman, R. T., Friedt, G. A., Kramer, A. R., & Hofstetter, M. A. (2014). Oral Chemotherapy Food and Drug Interactions: A Comprehensive Review of the Literature. Journal of Oncology Practice, 10(4), e255–e268. https://doi.org/10.1200/JOP.2013.001183
Shahar, N., & Larisch, S. (2020). Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance. Drug Resistance 52, 100712. https://doi.org/10.1016/j.drup.2020.100712
Shin, M. S., Kim, H. S., Lee, S. H., Park, W. S., Kim, S. Y., Park, J. Y., Lee, J. H., Lee, S. K., Lee, S. N., Jung, S. S., Han, J. Y., Kim, H., Lee, J. Y., & Yoo, N. J. (n.d.). Mutations of Tumor Necrosis Factor-related Apoptosis-inducing Ligand Receptor 1 (TRAIL-R1) and Receptor 2 (TRAIL-R2) Genes in Metastatic Breast Cancers.
Shoshan-Barmatz, V., Arif, T., &Shteinfer-Kuzmine, A. (2023). Apoptotic proteins with non-apoptotic activity: Expression and function in cancer. Apoptosis, 28(5), 730–753. https://doi.org/10.1007/s10495-023-01835-3
Sjöstedt, N., Holvikari, K., Tammela, P., & Kidron, H. (2017). Inhibition of Breast Cancer Resistance Protein and Multidrug Resistance Associated Protein 2 by Natural Compounds and Their Derivatives. Molecular Pharmaceutics, 14(1), 135–146. https://doi.org/10.1021/acs.molpharmaceut.6b00754
Snajdauf, M., Havlova, K., Vachtenheim, J., Ozaniak, A., Lischke, R., Bartunkova, J., Smrz, D., &Strizova, Z. (2021). The TRAIL in the Treatment of Human Cancer: An Update on Clinical Trials. Frontiers in Molecular Biosciences, 8, 628332. https://doi.org/10.3389/fmolb.2021.628332
Sodani, K., Patel, A., Kathawala, R. J., & Chen, Z.-S. (2012). Multidrug resistance associated proteins in multidrug resistance. Chinese Journal of Cancer, 31(2), 58–72. https://doi.org/10.5732/cjc.011.10329
Solon, A. L., Zaniewski, T. M., O’Brien, P., Clasby, M., Hancock, W. O., & Ohi, R. (2022). Synergy between inhibitors of two mitotic spindle assembly motors undermines an adaptive response. Molecular Biology of the Cell, 33(14), ar132. https://doi.org/10.1091/mbc.E22-06-0225
Sonar, S., & Lal, G. (2015).Role of Tumor Necrosis Factor Superfamily in Neuroinflammation and Autoimmunity.Frontiers in Immunology, 6. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2015.00364
Song, E. Z., Wang, X., Philipson, B. I., Zhang, Q., Thokala, R., Zhang, L., Assenmacher, C.-A., Binder, Z. A., Ming, G.-L., O’Rourke, D. M., Song, H., & Milone, M. C. (2022). The IAP antagonist birinapant enhances chimeric antigen receptor T cell therapy for glioblastoma by overcoming antigen heterogeneity. Molecular Therapy Oncolytics, 27, 288–304. https://doi.org/10.1016/j.omto.2022.11.004
Soria, J.-C., Smit, E., Khayat, D., Besse, B., Yang, X., Hsu, C.-P., Reese, D., Wiezorek, J., & Blackhall, F. (2010). Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. Journal of Clinical Oncology: 28(9), 1527–1533. https://doi.org/10.1200/JCO.2009.25.4847
Sriraman, S. K., Aryasomayajula, B., &Torchilin, V. P. (2014). Barriers to drug delivery in solid tumors. Tissue Barriers, 2, e29528. https://doi.org/10.4161/tisb.29528
Stefanski, C. D., Keffler, K., McClintock, S., Milac, L., & Prosperi, J. R. (2019). APC loss affects DNA damage repair causing doxorubicin resistance in breast cancer cells. Neoplasia, 21(12), 1143–1150. https://doi.org/10.1016/j.neo.2019.09.002
Statello L, Guo CJ, Chen LL, Huarte M. (2021) Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 22(2):96-118. https://doi.org/10.1038/s41580-020-00315-9.
Stylianopoulos, T., Munn, L. L., & Jain, R. K. (2018). Reengineering the Tumor Vasculature: Improving Drug Delivery and Efficacy. Trends in Cancer, 4(4), 258–259. https://doi.org/10.1016/j.trecan.2018.02.010
Sun, J., Wei, Q., Zhou, Y., Wang, J., Liu, Q., & Xu, H. (2017).A systematic analysis of FDA-approved anticancer drugs. BMC Systems Biology, 11(Suppl 5), 87. https://doi.org/10.1186/s12918-017-0464-7
Sun, Y., Li, J., Sun, Y., Zhao, R., Wang, L., Song, W., Wang, Z., Wang, J., Wei, L., Zhao, Y., Song, Y., & Hu, Z. (2019). A Stable Pep2-proapoptotic Peptide Inducing Apoptosis of Acute Myeloid Leukemia Cells by Down-Regulating EZH2. Cellular and Molecular Bioengineering, 13(2), 165–177. https://doi.org/10.1007/s12195-019-00605-z
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660
Tang, B., Tang, F., Wang, Z., Qi, G., Liang, X., Li, B., Yuan, S., Liu, J., Yu, S., & He, S. (2016). Upregulation of Akt/NF-κB-regulated inflammation and Akt/Bad-related apoptosis signaling pathway involved in hepatic carcinoma process: Suppression by carnosic acid nanoparticle. International Journal of Nanomedicine, 11, 6401–6420. https://doi.org/10.2147/IJN.S101285
Tao H, Cheng L, Yang R. (2020) Downregulation of miR-34a Promotes Proliferation and Inhibits Apoptosis of Rat Osteoarthritic Cartilage Cells by Activating PI3K/Akt Pathway. ClinInterv Aging. 16;15:373-385. https://doi.org/10.2147/CIA.S241855
Tashker, J. S., Olson, M., & Kornbluth, S. (2002). Post–Cytochrome c Protection from Apoptosis Conferred by a MAPK Pathway in Xenopus Egg Extracts. Molecular Biology of the Cell, 13(2), 393–401. https://doi.org/10.1091/mbc.01-06-0291
Teh, C. E., Peng, H., Luo, M.-X., Tan, T., Trussart, M., Howson, L. J., Chua, C. C., Muttiah, C., Brown, F., Ritchie, M. E., Wei, A. H., Roberts, A. W., Bryant, V. L., Anderson, M. A., Lindeman, G. J., Huang, D. C. S., Thijssen, R., & Gray, D. H. D. (2023). Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cells. Blood Advances, 7(12), 2733–2745. https://doi.org/10.1182/bloodadvances.2022008221
Terada, T., & Hira, D. (2015). Intestinal and hepatic drug transporters: Pharmacokinetic, pathophysiological, and pharmacogenetic roles. Journal of Gastroenterology, 50(5), 508–519. https://doi.org/10.1007/s00535-015-1061-4
Thapa, B., Kc, R., & Uludağ, H. (2020). TRAIL therapy and prospective developments for cancer treatment. Journal of Controlled Release, 326, 335–349. https://doi.org/10.1016/j.jconrel.2020.07.013
Tie, Y., Tang, F., Wei, Y.-Q., & Wei, X.-W. (2022). Immunosuppressive cells in cancer: Mechanisms and potential therapeutic targets. Journal of Hematology & Oncology, 15(1), 61. https://doi.org/10.1186/s13045-022-01282-8
Townsend, P. A., Kozhevnikova, M. V., Cexus, O. N. F., Zamyatnin, A. A., &Soond, S. M. (2021). BH3-mimetics: Recent developments in cancer therapy. Journal of Experimental & Clinical Cancer Research, 40(1), 355. https://doi.org/10.1186/s13046-021-02157-5
Traube, F. R., Brás, N. F., Roos, W. P., Sommermann, C. C., Diehl, T., Mayer, R. J., Ofial, A. R., Müller, M., Zipse, H., & Carell, T. (2022). Epigenetic Anti-Cancer Treatment With a Stabilized Carbocyclic Decitabine Analogue. Chemistry–A European Journal, 28(26), e202200640. https://doi.org/10.1002/chem.202200640
Tune, B. X. J., Sim, M. S., Poh, C. L., Guad, R. M., Woon, C. K., Hazarika, I., Das, A., Gopinath, S. C. B., Rajan, M., Sekar, M., Subramaniyan, V., Fuloria, N. K., Fuloria, S., Batumalaie, K., & Wu, Y. S. (2022). Matrix Metalloproteinases in Chemoresistance: Regulatory Roles, Molecular Interactions, and Potential Inhibitors. Journal of Oncology, 2022, 3249766. https://doi.org/10.1155/2022/3249766
Twomey, J. D., Kim, S.-R., Zhao, L., Bozza, W. P., & Zhang, B. (2015).Spatial dynamics of TRAIL death receptors in cancer cells. Drug Resistance Updates, 19, 13–21. https://doi.org/10.1016/j.drup.2015.02.001
Ulldemolins, A., Seras-Franzoso, J., Andrade, F., Rafael, D., Abasolo, I., Gener, P., & Schwartz Jr, S. (2021). Perspectives of nano-carrier drug delivery systems to overcome cancer drug resistance in the clinics. Cancer Drug Resistance, 4(1), 44–68. https://doi.org/10.20517/cdr.2020.59
von Pawel, J., Harvey, J. H., Spigel, D. R., Dediu, M., Reck, M., Cebotaru, C. L., Humphreys, R. C., Gribbin, M. J., Fox, N. L., & Camidge, D. R. (2014). Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Clinical Lung Cancer, 15(3), 188-196.e2. https://doi.org/10.1016/j.cllc.2013.12.005
Walker, Z. J., Xue, S., Jones, M. P., & Ravindran, A. V. (2021). Depression, Anxiety, and Other Mental Disorders in Patients With Cancer in Low- and Lower-Middle–Income Countries: A Systematic Review and Meta-Analysis. JCO Global Oncology, 7, GO.21.00056. https://doi.org/10.1200/GO.21.00056
Wang, H., Guo, M., Wei, H., & Chen, Y. (2021).Targeting MCL-1 in cancer: Current status and perspectives. Journal of Hematology & Oncology, 14(1), 67. https://doi.org/10.1186/s13045-021-01079-1
Wang, J., Tao, J., Jia, S., Wang, M., Jiang, H., & Du, Z. (2021). The Protein-Binding Behavior of Platinum Anticancer Drugs in Blood Revealed by Mass Spectrometry. Pharmaceuticals, 14(2), 104. https://doi.org/10.3390/ph14020104
Wang, M., Yu, F., Zhang, Y., Zhang, L., Chang, W., & Wang, K. (2022).The Emerging Roles of Circular RNAs in the Chemoresistance of Gastrointestinal Cancer. Frontiers in Cell and Developmental Biology, 10, 821609. https://doi.org/10.3389/fcell.2022.821609
Wang, X., Zhang, H., & Chen, X. (2019).Drug resistance and combating drug resistance in cancer. Cancer Drug Resistance, 2(2), 141–160. https://doi.org/10.20517/cdr.2019.10
Ward, G. A., Lewis, E. J., Ahn, J. S., Johnson, C. N., Lyons, J. F., Martins, V., Munck, J. M., Rich, S. J., Smyth, T., Thompson, N. T., Williams, P. A., Wilsher, N. E., Wallis, N. G., &Chessari, G. (2018). ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth. Molecular Cancer Therapeutics, 17(7), 1381–1391. https://doi.org/10.1158/1535-7163.MCT-17-0848
Wawruszak, A., Borkiewicz, L., Okon, E., Kukula-Koch, W., Afshan, S., &Halasa, M. (2021).Vorinostat (SAHA) and Breast Cancer: An Overview. Cancers, 13(18), 4700. https://doi.org/10.3390/cancers13184700
Wolf, A. M. (2021). The tumor suppression theory of aging. Mechanisms of Ageing and Development, 200, 111583. https://doi.org/10.1016/j.mad.2021.111583
World Cancer Day 2023: Close the care gap - PAHO/WHO | Pan American Health Organization. (n.d.). Retrieved February 17, 2024, from https://www.paho.org/en/campaigns/world-cancer-day-2023-close-care-gap
Wu, B., Zhang, Y., Yu, Y., Zhong, C., Lang, Q., Liang, Z., Lv, C., Xu, F., & Tian, Y. (2021). Long Noncoding RNA H19: A Novel Therapeutic Target Emerging in Oncology Via Regulating Oncogenic Signaling Pathways. Frontiers in Cell and Developmental Biology, 9. https://doi.org/10.3389/fcell.2021.796740
Yang, C., Zhang, J., Ma, Y., Wu, C., Cui, W., & Wang, L. (2020). Histone methyltransferase and drug resistance in cancers. Journal of Experimental & Clinical Cancer Research, 39(1), 173. https://doi.org/10.1186/s13046-020-01682-z
Yang, H., Geng, Y.-H., Wang, P., Zhang, H.-Q., Fang, W.-G., & Tian, X.-X. (2022). Extracellular ATP promotes breast cancer chemoresistance via HIF-1α signaling. Cell Death & Disease, 13(3), 199. https://doi.org/10.1038/s41419-022-04647-6
Yang, L., Kumar, B., Shen, C., Zhao, S., Blakaj, D., Li, T., Romito, M., Teknos, T. N., & Williams, T. M. (2019). LCL161, a SMAC mimetic, Preferentially Radiosensitizes Human Papillomavirus Negative Head and Neck Squamous Cell Carcinoma. Molecular Cancer Therapeutics, 18(6), 1025–1035. https://doi.org/10.1158/1535-7163.MCT-18-1157
Yang, R., Yi, M., & Xiang, B. (2022). Novel Insights on Lipid Metabolism Alterations in Drug Resistance in Cancer. Frontiers in Cell and Developmental Biology, 10. https://www.frontiersin.org/articles/10.3389/fcell.2022.875318
Yap, T. A., Daver, N., Mahendra, M., Zhang, J., Kamiya-Matsuoka, C., Meric-Bernstam, F., Kantarjian, H. M., Ravandi, F., Collins, M. E., Francesco, M. E. D., Dumbrava, E. E., Fu, S., Gao, S., Gay, J. P., Gera, S., Han, J., Hong, D. S., Jabbour, E. J., Ju, Z., … Konopleva, M. (2023). Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: Phase I trials. Nature Medicine, 29(1), 115–126. https://doi.org/10.1038/s41591-022-02103-8
Yee-Lin, V., Pooi-Fong, W., &Soo-Beng, A. K. (2018). Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment. Mini Reviews in Medicinal Chemistry, 18(2), 173–183. https://doi.org/10.2174/1389557517666170717125821
Yeldag, G., Rice, A., & del Río Hernández, A. (2018). Chemoresistance and the Self-Maintaining Tumor Microenvironment. Cancers, 10(12), 471. https://doi.org/10.3390/cancers10120471
Zhang, L., Sun, L., Wang, L., Wang, J., Wang, D., Jiang, J., Zhang, J., & Zhou, Q. (2023). Mitochondrial division inhibitor (mdivi-1) inhibits proliferation and epithelial-mesenchymal transition via the NF-κB pathway in thyroid cancer cells. Toxicology in Vitro, 88, 105552. https://doi.org/10.1016/j.tiv.2023.105552
Zhang, X., Tang, N., Hadden, T. J., & Rishi, A. K. (2011). Akt, FoxO and regulation of apoptosis. Biochimica Et BiophysicaActa, 1813(11), 1978–1986. https://doi.org/10.1016/j.bbamcr.2011.03.010
Zhang, Z.-W., Zhao, X.-S., Guo, H., & Huang, X.-J. (2023). The role of m6A demethylase FTO in chemotherapy resistance mediating acute myeloid leukemia relapse. Cell Death Discovery, 9(1), Article 1. https://doi.org/10.1038/s41420-023-01505-y
Zhao, X., Sun, W., Puszyk, W. M., Wallet, S., Hochwald, S., Robertson, K., & Liu, C. (2017). Focal adhesion kinase inhibitor PF573228 and death receptor 5 agonist lexatumumab synergistically induce apoptosis in pancreatic carcinoma. Tumour Biology, 39(5), 1010428317699120. https://doi.org/10.1177/1010428317699120
Zhao, Z., Li, T., Sun, L., Yuan, Y., & Zhu, Y. (2023). Potential mechanisms of cancer-associated fibroblasts in therapeutic resistance. Biomedicine & Pharmacotherapy, 166, 115425. https://doi.org/10.1016/j.biopha.2023.115425
Zhu, L., Zhu, Y., Li, F., Meng, Y., Wang, H., Xu, W., Luo, J., Wang, X., Feng, L., & Jin, H. (2023). RNautophagic regulation of DNMT3a‐dependent DNA methylation by Linc00942 enhances chemoresistance in gastric cancer. Clinical and Translational Medicine, 13(7), e1337. https://doi.org/10.1002/ctm2.1337
Zou, B., Lee, V. H. F., & Yan, H. (2018). Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis. BMC Bioinformatics, 19, 88. https://doi.org/10.1186/s12859-018-2093-6
Statistics
1523 Views | 1011 Downloads
How to Cite
Halder, K. (2024). Chemotherapy Resistance in Cancer: Mechanism and Roadmap to Evade Exploring Apoptosis. International Journal of Advancement in Life Sciences Research, 7(2), 17-40. https://doi.org/https://doi.org/10.31632/ijalsr.2024.v07i02.003
Section
Review Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
.